Pharmaceutical composition containing pyrazole ether compound and application thereof

Abstract

The invention provides a pharmaceutical composition containing a pyrazole ether compound and application of the pharmaceutical composition, the pharmaceutical composition comprises an effective component A and an effective component B. The effective component A is a pyrazole ether compound with a structure shown in a formula I; and the effective component B is selected from any one or a combination of at least two of azole bactericides, mitochondrial electron transport chain compound III inhibitor bactericides, SDHI bactericides, multi-site contact type bactericides or other bactericides. In the invention, the effective component A and the effective component B have a synergistic effect, so that the pharmaceutical composition has higher biological activity and favorable or wider active spectrum, can reduce the application amount of compounds and compositions required for effectively controlling phytopathogens, and has longer lasting activity.

Description

Technical Field

[0001] The invention belongs to the technical field of plant protection fungicides and relates to a pharmaceutical composition containing a pyrazole ether compound and application thereof. Background Art

[0002] The growth process of crops such as agriculture, horticulture, vegetables, fruit trees, and cash crops is often affected by plant diseases, insect pests, and weeds, which leads to reduced crop yields, reduced product commerciality, economic losses, or some social harm. Therefore, it is of great significance to develop effective plant protection products against plant diseases and insect pests.

[0003] CN116003322A discloses some pyrazole ether compounds as fungicides having fungicidal effects. However, the biological properties of these known compounds and their compositions are not completely satisfactory for controlling or preventing plants from being infected by phytopathogenic fungi.

[0004] Although numerous fungicidal compounds and compositions belonging to a variety of different chemical classes have been or are being developed for use as fungicides in crops of useful plants, crop tolerance and activity against specific phytopathogenic fungi do not always meet the needs of agricultural practice in many respects.

[0005] In addition, fungicides of different structural types are widely used in various crops, but the fungicidal spectrum of a single structural type of fungicide is limited. It is common for different diseases to occur at the same time, and it is necessary to use a single drug to prevent and control multiple diseases.

[0006] Therefore, there is still a continuing need to discover new compositions with superior properties for controlling or preventing plant pathogens from infecting plants, for example, higher biological activity, a favorable or broader spectrum of activity, combined synergistic or synergistic compositions, or the ability to reduce the application rates of compounds and compositions required for effective control of plant pathogens, higher tolerance, or longer lasting activity, thereby enabling effective tolerance and / or resistance management practices. Summary of the invention

[0007] In view of the shortcomings of the prior art, the present invention aims to provide a pharmaceutical composition containing a pyrazole ether compound and its application. The pharmaceutical composition provided by the present invention has a synergistic effect and can prevent and treat a variety of agricultural, forestry and horticultural diseases.

[0008] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0009] In one aspect, the present invention provides a pharmaceutical composition containing a pyrazole ether compound, wherein the pharmaceutical composition comprises an active ingredient A and an active ingredient B, wherein the active ingredient A is a pyrazole ether compound having a structure shown in Formula I:

[0010]

[0011] R1 is selected from hydrogen, halogen, cyano, nitro, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, heptafluoroisopropyl, methoxy, difluoromethoxy or trifluoromethoxy;

[0012] R2 is selected from halogen, methyl, difluoromethyl, trifluoromethyl, methoxy, difluoromethoxy or trifluoromethoxy;

[0013] R3 is selected from hydrogen, halogen, methyl, difluoromethyl or trifluoromethyl;

[0014] n represents an integer from 0 to 5;

[0015] The active ingredient B is selected from any one or a combination of at least two of azole fungicides, mitochondrial electron transport chain complex III inhibitor fungicides, SDHI fungicides, multi-site contact fungicides or other fungicides.

[0016] In the present invention, the active ingredient A and the active ingredient B act synergistically, so that the pharmaceutical composition has higher biological activity, a favorable or wider activity spectrum, can reduce the application amount of the compounds and compositions required for effectively controlling plant pathogens, and has longer lasting activity.

[0017] In the present invention, the halogen is selected from fluorine, chlorine, bromine or iodine.

[0018] Preferably, the active ingredient A is any one of the following compounds:

[0019]

[0020] More preferably, the active ingredient A is selected from Compound 2, Compound 3 or Compound 6.

[0021] Preferably, the active ingredient B is any one or a combination of at least two of the fungicides B1 to B5 described below.

[0022] (B1) azole fungicides, including pentoconazole, ethoconazole, ipiconazole, bifenthrin, oxadiazole, cyproconazole, fenpropimorph, diniconazole, epoxiconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imipenem, clofoconazole, metconazole, myclobutanil, penconazole, propiconazole, silyconazole, tebuconazole, tetrafluconazole, triadimefon, triadimenol, trimethoprim-butyl, prothioconazole, Fluoxytioconazole, imazalil, oxadiazole, pyraclostrobin, prochloraz, trifloxystrobin, triamcinol, trimethoprim-butyl, prochloraz, triflumizole, triamcinol, trifloxystrobin ...

[0023] (B2) mitochondrial electron transport chain complex III inhibitors, including pyraclostrobin, fluoxastrobin, azoxystrobin, pyraclostrobin, syringosterone, enoxastrobin, flutoxifen, picoxystrobin, pyraclostrobin, pyraclostrobin, chlorpyrifos, oxadix, oxazolidinone, pyraclostrobin, enoxastrobin, chlorpyrifos, famoxadone, pyraclostrobin, enoxastrobin, fenoxystrobin, oxazolidinone, pyraclostrobin, fenoxystrobin, mandestrobin;

[0024] (B3) SDHI fungicides, including flutolanil, mefenamic acid, isopyram, fluopyram, triflupyramide, fenfuram, oxycarboxin, thiofuran, benzovinflumazole, bixafen, fluinoxadone, fluopyram, fluopyram, furopyram, inpyrfluxam, pyraclostrobin, fluopyram, penthiopyrad, flutolanil, isoflucypram, fluopyram, boscalid, furamide, isoflucypram, bixafen, fenoxadone or pyrapropoyne;

[0025] (B4) Multi-site contact fungicides, including: copper preparations, sulfur, chlorothalonil, ferram, mancozeb, maneb, methocarb, propineb, thiram, zinc thiazole, mancozeb, thiram, captan, captafol, folpet, benzylfluanid, tolylfluanid, biguanide salts, fluoroimide, dicyanoanthraquinone, mancozeb, and sulfamethoxazole;

[0026] (B5) Other fungicides: bensulfuron, bensulfuron-M, furalaxyl, metalaxyl, metalaxyl-M, furamide, oxadixyl, pyrimidine sulfonate, dimethoate, pyrimidine, octhiocarb, oxadixyl, quinacridone, ipflufenoquin; benomyl, carbendazim, oxadixyl, thiophanate-methyl, thiophanate-methyl, ethotripsy, benomyl, pencuron, fluopyram, fluopyram, cyanothiocarb, benomyl, Fyriofenone, Fluopyram, Tetracycline, Cyazofamid, Indazole Sulfonamide, Fenpicoxamid, Pyridine, Nizostrobin, Fluazinam, Triphenyltin Acetate, Triphenyltin Chloride, Triphenyltin Hydroxide, Silthiopyrad, Azopyrad; Cyprodinil, Cyprodinil, Cyprodinil, Methionine, Kasugamycin, Streptomycin, Oxytetracycline, Phenoxyquin, Propoxyquin, Fenzoline, Flutoxil, Ethiocyanate, Sclerotin, Iprodione, Procymidone, Vinclozolin, Rice Blast, Difenothioate, Isothioate, Biphenyl, Dimethoate, Chlornitril, Pentachloronitrobenzene, Tetrachloronitrobenzene, Cyproconazole, Cyproconazole, Iodocarb, Natamycin, Fluoxapiproline, Dimethylmorpholine, Dodecamorpholine, Tridecamorpholine, Butylmorpholine, Fenpropidin, Powdery Mildew Ling, spiroxafil, amine pyraclostrobin, cyclamoxadone, naftifine, terbinafine, polyoxin, dimethomorph, flumorph, butylpyraclostrobin, dimethomorph, benzathiapyr, valerian, valerian; tetrachlorophthalide, pyroquilone, tricyclazole, dichlorocyanamide, cyclopropane amide, rice blastamide, Tolprocarb, activated ester, allylbenzazole, thiazolamide, isothiazolamide, kelp polysaccharide, Reynoutria sachalinensis (a plant extract), P6 Bacillusmycoides (bacteria), Cell walls of Saccharomyces cerevisiae Strain LAS117 (fungus), Fosetyl-aluminum, Phosphite, Cymoxanil, Chlorphenamine, Imidazolidinone, Sulfonamide, Dapoxetine, Cyfluanid, Cyproconazole, Tetrazolylpyram, Isobutylethoxyquin, Jinggangmycin, Dodecacyclic Morpholine, Flutianil, Ipflufenoquin, Quinofumelin, Aminopyrifen, dipymetitrone, Flufenoxadiazam, Metarylpicoxamid, Flumetylsulforim or Cytoxanil.

[0027] Preferably, the active ingredient B is selected from any one or a combination of at least two of the following groups B1-B5 fungicides:

[0028] (B1) Azoles fungicides, including: cyproconazole, fenpropimorph, epoxiconazole, hexaconazole, clofoconazole, metconazole, myclobutanil, propiconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triclosan, prothioconazole, fluoxytioconazole, imazalil, prochloraz or pyraclostrobin;

[0029] (B2) mitochondrial electron transport chain complex III inhibitors, including fluoxastrobin, azoxystrobin, pyraclostrobin, syringosterone, enoxastrobin, picoxystrobin, pyraclostrobin, oxazolidinone, chlorpyrifos, famoxadone, oxazolidinone, enoxamyl, fenoxystrobin, oxazolidinone, oxazolidinone, fenoxamyl, fenoxystrobin, oxazolidinone, fenoxamyl, fenoxamyl, or mandestrobin;

[0030] (B3) SDHI fungicides, including: Flutolanil, Isothiopyrad, Fluopyram, Triflupyridam, Fenfuram, Thifuroxamide, Benzovinflumazole, Bixafen, Fluinoxadone, Fluopyram, Furapyram, Inpyrfluxam, Pyrafenib, Fluopyram, Penthiopyrad, Fluopyram, Isoflucypram, Fluopyram, Boscalid, Mefuroxamide, Isoflupyram, Bixafen, Fenfuram or Pyrapropoyne;

[0031] (B4) Multi-site contact fungicides, the group consisting of: copper preparations, sulfur, thiophanate-methyl, mancozeb, propineb, thiram, zinc thiabendate or captan;

[0032] (B5) Other fungicides: Metalaxyl, Metalaxyl-M, Oxadixyl, Ethylpyrimidine Sulfonate, Ethylpyrimidine, Quinclorac, Benomyl, Carbendazim, Thiabendazole, Thiophanate, Thiophanate-methyl, Dithiocarb, Fluopyram, Fluopyram, Cyanocobacteramide, Cyanoprolin, Metraconazole, Pyriofenone, Fluopyram, Tetracycline, Cyazofamid, Indazole Sulfonamide, Fenpicoxamid, Pyridine Bactamide, Nibenstrobin, Fluazinam, Sithiopyram, Cyprodinil, Cyprodinil, Pyrimidine, Pyramid, Pyrimidine, Pyrimidine, Phenoxyquin, Propoxyquin, Fluclozolin, Fluclozolin, Ethylpyrimidine, Sclerotin, Iprodione, Procymidone, Vinclozolin, Paddyfield, Isoprofen, Fenoxycarb, Iodocarb, Natamycin, Fluoxapiproline, Fluoxaproline , spiroxabiocin, fenpyraclostrobin, fenpyraclostrobin, polyoxin, oxazolidinone, flumorph, butylpyraclostrobin, dimethomorph, benzathiapiprolin, valeric acid, valeric acid, pyroquinone, tricyclazole, dichloropyraclostrobin, cyproconazole, rice blastamide, Tolprocarb, activated ester, allylbenzazole, thiazolamide, isothiazamide, cymoxanil, cyfluthrin, pyrimidine, tetrazolylpyram, isobutylethoxyquin, Jinggangmycin, dodecacyclic morpholine, Flutianil, Ipflufenoquin, Quinofumelin, Aminopyrifen, Dipymetitrone, Flufenoxadiazam, Metarylpicoxamid, Flumetylsulforim or cintamidine.

[0033] More preferably, the active ingredient B is selected from any one or a combination of at least two of the following bactericides B1-B5:

[0034] (B1) Azoles fungicides, including: cyproconazole, difenoconazole, epoxiconazole, hexaconazole, clofoconazole, metconazole, propiconazole, tebuconazole, prothioconazole, Fluoxytioconazole, prochloraz or pyraclostrobin;

[0035] (B2) mitochondrial electron transport chain complex III inhibitors, including: azoxystrobin, pyraclostrobin, syringystrobin, enoxastrobin, picoxystrobin, fenoxastrobin or mandestrobin;

[0036] (B3) SDHI fungicides, including: Fluopyram, Triflupyridam, Benzovinfluxazole, Bixafen, Fluopyram, Inpyrfluxam, Fluopyram, Penthiopyrad, Fluopyram, Isoflucypram, Fluopyram, Boscalid, Bixafen, Fenoxam or Pyrapropoyne;

[0037] (B4) Multi-site contact fungicides, including: chlorothalonil, mancozeb, propineb, thiabendazim or captan;

[0038] (B5) Other fungicides: Metalaxyl-M, Ethiopyrimidine sulfonate, Ethiopyrimidine, Quinclorac, Benomyl, Carbendazim, Methyl Thiophanate, Dithiocarb, Fluopyram, Fluopyram, Cyanocobamide, Cyanopyram, Metraconazole, Pyriofenone, Cyazofamid, Indazolesulfamide, Fenpicoxamid, Nifenoxystrobin, Fluazinam, Cyprodinil, Myrimidine, Myrimidine, Fenpicoxamide, Fludioxonil, Sclerotinol, Iprodione, Procymidone, Vinclorac, Iodocarb, Iodocarb, Natamycin, Fluoxapiproline, Spirocyclanil, Amine Pyraclostrobin, Fenhexamid, Polyoxin, Dimethomorph, Flumorph, Butamorph, Dimethomorph, Benthiopyrad, Valamycin, Valicylide, Pyroquilone, Tricyclazole, Cyproconazole, Papyramide, Tolprocarb, Activated Ester, Cymoxanil, Tetrazolylpyram, Jinggangmycin, Flutianil, Ipflufenoquin, Quinofumelin, Aminopyrifen, Dipymetitrone, Flufenoxadiazam, Metarylpicoxamid, Flumetylsulforim, or Cyproconazole.

[0039] Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B1.

[0040] Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B2.

[0041] Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B3.

[0042] Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B4.

[0043] Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B5.

[0044] Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B1 and B2.

[0045] Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B1 and B3.

[0046] Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B1 and B4.

[0047] Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B1 and B5.

[0048] Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B2 and B3.

[0049] Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B2 and B4.

[0050] Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B2 and B5.

[0051] Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B3 and B4.

[0052] Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B3 and B5.

[0053] Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B4 and B5.

[0054] Preferably, the weight ratio of the active ingredient A to the active ingredient B is 1:0.02-100, for example 1:0.02, 1:0.05, 1:0.1, 1:0.5, 1:1, 1:3, 1:5, 1:8, 1:10, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90 or 1:100.

[0055] Preferably, the active ingredient B is any one of the following B1: cyproconazole, difenoconazole, epoxiconazole, hexaconazole, clofoconazole, metconazole, propiconazole, tebuconazole, prothioconazole, Fluoxytioconazole, prochloraz or pyraclostrobin, and the weight ratio of the active ingredient A to the active ingredient B1 is 1:0.02-50, for example, 1:0.02, 1:0.05, 1:0.1, 1:0.5, 1:1, 1:3, 1:5, 1:8, 1:10, 1:20, 1:30, 1:40 or 1:50, preferably 1:0.05-40.

[0056] Preferably, the active ingredient B is any one of the following B2: azoxystrobin, pyraclostrobin, syringoxystrobin, enoxastrobin, picoxystrobin, fenoxastrobin, Mandestrobin, and the weight ratio of the active ingredient A to the active ingredient B2 is 1:0.02-50, for example, 1:0.02, 1:0.05, 1:0.1, 1:0.5, 1:1, 1:3, 1:5, 1:8, 1:10, 1:20, 1:30, 1:40 or 1:50, preferably 1:0.025-40.

[0057] Preferably, the active ingredient B is any one of the following B3: Fluopyram, Triflupyridam, Benzovinflumizone, Bixafen, Fluopyram, Inpyrfluxam, Fluopyram, Penthiopyrad, Fluopyram, Isoflucypram, Fluopyram Hydroxystrobin, Boscalid, Bixafen, Difenoconazole or Pyrapropoyne, and the weight ratio of the active ingredient A to the active ingredient B3 is 1:0.02-50, for example, 1:0.02, 1:0.05, 1:0.1, 1:0.5, 1:1, 1:3, 1:5, 1:8, 1:10, 1:20, 1:30, 1:40 or 1:50, preferably 1:0.025-40.

[0058] Preferably, the active ingredient B is any one of the following B4: chlorothalonil, mancozeb, propineb, zinc thiazole or captan, and the weight ratio of the active ingredient A to the active ingredient B4 is 1:0.02-100, for example, 1:0.02, 1:0.05, 1:0.1, 1:0.5, 1:1, 1:3, 1:5, 1:8, 1:10, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90 or 1:100, preferably 1:0.033-20.

[0059] Preferably, the active ingredient B is any one of the following B5: metalaxyl-M, ethimolsulfonate, ethimol, quinoline, benomyl, carbendazim, methylthiophanate, ethotripsy, benomyl, fluopyram, fluopyram, cyanothiocarb, metrafenone, pyriofenone, cyazofamid, indazolesulfamide, fenpicoxamid, nitrobenzene, fluazinam, cyprodinil, pyrimidine, pyrimidine, fenpicoxamid, fenpyroximate, fluazinam, pyrimidine, fenpyroximate ... , Fludioxonil, Sclerotinol, Iprodione, Procymidone, Vinclozolin, Rice Blast, Isoproxil, Cyproconazole, Iodocarb, Natamycin, Fluoxapiproline, Spirocyclamide, Amitriptyline, Cyclohexanil, Polyoxin, Dimethomorph, Flumorph, Butyroxanil, Dimethomorph, Benthiopyrad, Valicylide, Valamix, Pyroquinone, Tricyclazole, Cyproconazole , pyrimethamine, tolprocarb, activated ester, cymoxanil, tetrazolium pyrrolidone, Jinggangmycin, Flutianil, Ipflufenoquin, Quinofumelin, Aminopyrifen, Dipymetitrone, Flufenoxadiazam, Metarylpicoxamid, Flumetylsulforim or cintamidine, the weight ratio of active ingredient A to active ingredient B5 is 1:0.02-100, for example 1:0.02, 1:0.05, 1:0.1, 1:0.5, 1:1, 1:3, 1:5, 1:8, 1:10, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90 or 1:100, preferably 1:0.033-40.

[0060] Preferably, the active ingredient B is a combination of B1 and B2, the active ingredient A is any one of compound 2, compound 3 or compound 6, the active ingredient B1 is any one of cyproconazole, difenoconazole, epoxiconazole, hexaconazole, clofoconazole, metconazole, propiconazole, tebuconazole, prothioconazole, Fluoxytioconazole, prochloraz or pyraclostrobin, and the active ingredient B2 is any one of azoxystrobin, pyraclostrobin, eucomycin, Any one of ester, enoxastrobin, picoxystrobin, fenoxystrobin or Mandestrobin, the weight ratio of the active ingredient A to the active ingredient (B1+B2) is 1:0.02-50, for example 1:0.02, 1:0.05, 1:0.1, 1:0.5, 1:1, 1:3, 1:5, 1:8, 1:10, 1:20, 1:30, 1:40 or 1:50, preferably 1:0.05-30.

[0061] Preferably, the active ingredient B is a combination of B1 and B3; the active ingredient A is any one of compound 2, compound 3, and compound 6; the active ingredient B1 is any one of cyproconazole, prothioconazole, difenoconazole, epoxiconazole, diniconazole, flusilazole, flutriafol, tebuconazole, hexaconazole, myclobutanil, penconazole, propiconazole, or tetrafluconazole; the active ingredient B3 is any one of fluopyram, triflupyridam, benzovinflumazole, bixafen, fluopyram, Inpyrfluxam, fluopyram, penthiopyrad, and penthiopyrad. , any one of fluazifop, Isoflucypram, fluazifop, boscalid, bifenthrin, fenpropimorph or pyrapropoyne, the weight ratio of active ingredient A to active ingredient (B1+B3) is 1:0.02-50, for example 1:0.02, 1:0.05, 1:0.1, 1:0.5, 1:1, 1:3, 1:5, 1:8, 1:10, 1:20, 1:30, 1:40 or 1:50, preferably 1:0.025-40.

[0062] Preferably, the active ingredient B is a combination of B1 and B4; the active ingredient A is any one of compound 2, compound 3 or compound 6; the active ingredient B1 is any one of cyproconazole, prothioconazole, difenoconazole, epoxiconazole, diniconazole, flusilazole, flutriafol, tebuconazole, hexaconazole, myclobutanil, penconazole, propiconazole or tetrafluconazole; the active ingredient B4 is any one of chlorothalonil, mancozeb, propineb, thiabendazole or captan. Any one of the above, the weight ratio of active ingredient A to active ingredient (B1+B4) is 1:0.02-100, for example 1:0.02, 1:0.05, 1:0.1, 1:0.5, 1:1, 1:3, 1:5, 1:8, 1:10, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90 or 1:100, preferably 1:0.025-64.

[0063] Preferably, the active ingredient B is a combination of B1 and B5; the active ingredient A is any one of compound 2, compound 3 or compound 6; the active ingredient B1 is any one of cyproconazole, prothioconazole, difenoconazole, epoxiconazole, diniconazole, flusilazole, flutriafol, tebuconazole, hexaconazole, myclobutanil, penconazole, propiconazole or tetrafluconazole; the active ingredient B5 is any one of metalaxyl-M, ethiprole sulfonate, ethiprole, quinacridone, benomyl, carbendazim, methylthiophanate, ethotripsy, fluopyram, and fluopyram. , Fluoxazolidinone, Cyanocobacterium butyl, Metraconazole, Pyriofenone, Cyazofamid, Indazolesulfamide, Fenpicoxamid, Nizobacter butyl, Fluazinam, Cyprodinil, Metraconazole, Metraconazole, Fenpicoxamid, Fludioxonil, Sclerotinol, Iprodione, Procymidone, Vinclozolin, Rice Blast, Isoprofen, Iodocarb, Natamycin, Fluoxapiproline, Spirocyclamide, Amitriptyline, Cyproconazole, Polymyxin B , Dimethomorph, Flumorph, Butyromorph, Dimethomorph, Benthiopyrad, Valamycin, Valamycin, Pyroquinone, Tricyclazole, Cyproconazole, Padoxamide, Tolprocarb, Activated Ester, Cymoxanil, Tetrazolylpyram, Jinggangmycin, Flutianil, Ipflufenoquin, Quinofumelin, Aminopyrifen, Dipymetitrone, Flufenoxadiazam, Metarylpico Any one of xamid, Flumetylsulforim or cintamidine, the weight ratio of active ingredient A to active ingredient (B1+B5) is 1:0.02-100, for example 1:0.02, 1:0.05, 1:0.1, 1:0.5, 1:1, 1:3, 1:5, 1:8, 1:10, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90 or 1:100, preferably 1:0.025-25.

[0064] Preferably, the active ingredient B is a combination of B2 and B3; the active ingredient A is any one of compound 2, compound 3 or compound 6; the active ingredient B2 is any one of azoxystrobin, pyraclostrobin, syringosterone, enoxastrobin, picoxystrobin, fenoxastrobin or Mandestrobin; the active ingredient B3 is fluopyram, triflupyridam, benzovinflumizone, bixafen, fluopyram, inpyrfluxam, fluopyram, penthiopyrad, fluopyram, and fluopyram. , Isoflucypram, fluopicolide, boscalid, bifenthrin, fenpropimorph or pyrapropoyne, the weight ratio of active ingredient A: active ingredient (B2+B3) is 1:0.02-50, for example 1:0.02, 1:0.05, 1:0.1, 1:0.5, 1:1, 1:3, 1:5, 1:8, 1:10, 1:20, 1:30, 1:40 or 1:50, preferably 1:0.04-25.

[0065] Preferably, the active ingredient B is a combination of B2 and B4; when the active ingredient A is any one of compound 2, compound 3 or compound 6, the active ingredient B2 is any one of azoxystrobin, pyraclostrobin, syringoxystrobin, enoxastrobin, picoxystrobin, fenoxystrobin or Mandestrobin, and the active ingredient B4 is any one of thiophanate-methyl, mancozeb, propineb, zinc thiazole or captan, and the weight ratio of the active ingredient A to the active ingredient (B2+B4) is 1:0.02-100, for example 1:0.02, 1:0.05, 1:0.1, 1:0.5, 1:1, 1:3, 1:5, 1:8, 1:10, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90 or 1:100, preferably 1:0.033-20.

[0066] Preferably, the active ingredient B is a combination of B2 and B5; the active ingredient A is any one of compound 2, compound 3 or compound 6; the active ingredient B2 is any one of azoxystrobin, pyraclostrobin, syringosterone, enoxastrobin, picoxystrobin, fenoxystrobin and Mandestrobin; the active ingredient B5 is any one of metalaxyl-M, pyrimidine sulfonate, pyrimidine, quinclorac, benomyl, carbendazim, methylthiophanate, ethotripsy, zoxanil, fluopyram, fluopyram, cyanamide, Strombolin, Metraconazole, Pyriofenone, Cyazofamid, Indazolesulfamide, Fenpicoxamid, Nizostrobin, Fluazinam, Cyprodinil, Cyprodinil, Pyrimethanil, Fenpicoxamid, Fludioxonil, Sclerotinol, Iprodione, Procymidone, Vinclozolin, Rice Blast, Isoprofen, Cyproconazole, Iodocarb, Natamycin, Fluoxapiproline, Spirocyclamide, Amitriptyline, Cyproconazole, Polyoxin, Enoyl Morpholine, Flumorph, Butyromorph, Dipyrimidine, Benthiopyrad, Valicin, Valinamide, Pyroquinone, Tricyclazole, Cyproconazole, Blastamide, Tolprocarb, Activated Ester, Cymoxanil, Tetrazolylpyrazone, Jinggangmycin, Flutianil, Quinofumelin, Aminopyrifen, Dipymetitrone, Flufenoxadiazam, Metarylpicoxamid , Flumetylsulforim or cintamidine, the weight ratio of active ingredient A to active ingredient (B2 + B5) is 1:0.02-100, for example 1:0.02, 1:0.05, 1:0.1, 1:0.5, 1:1, 1:3, 1:5, 1:8, 1:10, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90 or 1:100, preferably 1:0.05-20.

[0067] Preferably, the active ingredient B is a combination of B3 and B4; the active ingredient A is any one of compound 2, compound 3 or compound 6, and the active ingredient B3 is any one of fluopyram, triflupyridam, benzovinflumazole, bixafen, fluopyram, inpyrfluxam, fluopyram, penthiopyrad, fluoxazolidinone, isoflurane, fluopyram, boscalid, bixafen, fenfrac, and Pyrapropoyne, The active ingredient B4 is any one of thiophanate-methyl, mancozeb, propineb, zinc thiazole or captan, and the weight ratio of the active ingredient A to the active ingredient (B3+B4) is 1:0.02-100, for example 1:0.02, 1:0.05, 1:0.1, 1:0.5, 1:1, 1:3, 1:5, 1:8, 1:10, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90 or 1:100, preferably 1:0.05-40.

[0068] Preferably, the active ingredient B is a combination of B3 and B5; the active ingredient A is any one of compound 2, compound 3 or compound 6, the active ingredient B3 is any one of: fluopyram, triflupyridam, benzovinflumazole, bixafen, fluopyram, Inpyrfluxam, fluopyram, penthiopyrad, fluoxazolidinone, Isoflucypram, fluopyram hydroxylamine, boscalid, bixafen, difenoconazole or Pyrapropoyne, and the active ingredient B5 is any one of: metalaxyl-M, ethiprole. Sulfonate, Ethylpyrimidine, Quinclorac, Benomyl, Carbendazim, Methyl Thiophanate, Dithiocarb, Zoxanil, Fluopyram, Fluopyram, Cyanocobamide, Cyanopyram, Metraconazole, Pyriofenone, Cyazofamid, Indazole Sulfonamide, Fenpicoxamid, Nibifenamide, Fluazinam, Cyprodinil, Myrimidine, Myrimidine, Fenpicoxamid, Fludioxonil, Sclerotinol, Iprodione, Procymidone, Vinclorac, Paddyfield, Isoprodolil, Cyproconazole, Iodocarb, Natamycin, Fluoxapiprol, ine, Spirocyclamide, Amitripyrin, Cyclohexanil, Polyoxin, Dimethomorph, Flumorph, Butyropyrin, Dimethomorph, Benthiopyrad, Valamycin, Valamycin, Pyroquilone, Tricyclazole, Cyproconazole, Padoxamide, Tolprocarb, Activated Ester, Cymoxanil, Tetrazolylpyram, Jinggangmycin, Flutianil, Ipflufenoquin, Quinofumelin, Aminopyrifen, Dipymetitrone, Flufenoxadiaz When any one of am, Metarylpicoxamid, Flumetylsulforim or Octofenamid is used, the weight ratio of active ingredient A to active ingredient (B3+B5) is 1:0.02-100, for example 1:0.02, 1:0.05, 1:0.1, 1:0.5, 1:1, 1:3, 1:5, 1:8, 1:10, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90 or 1:100, preferably 1:0.025-40.

[0069] Preferably, the active ingredient B is a combination of B4 and B5, the active ingredient A is any one of compound 2, compound 3 or compound 6, the active ingredient B4 is any one of chlorothalonil, mancozeb, propineb, zinc thiazole or captan, and the active ingredient B5 is any one of metalaxyl-M, ethimol sulfonate, ethimol, quinclorac, benomyl, carbendazim, methylthiophanate, ethotripsy, zoxanil, fluopyram, fluopyram, cyanothiocarb, metrafenone, pyriofenone, cyanothiocarb ... Fenpicoxamid, Indazolesulfamide, Fenpicoxamid, Nizostrobin, Fluazinam, Cyprodinil, Cyprodinil, Cyprodinil, Fenpicoxamid, Fludioxonil, Sclerotinol, Iprodione, Procymidone, Vinclozolin, Isoprofen, Isoprofen, Iodocarb, Natamycin, Fluoxathiapiproline, Fluoxapiproline, Spirocyclamide, Amitriptyline, Cyclohexanil, Polyoxin, Dimethomorph, Flumorph, Butyroxan, Dimethomorph, Benthiopyrad, Valamycin, Valamycin, Pyroquilone, Tricyclazole, Cyproconazole, Blastamide, Tolprocarb, Activated Ester, Cymoxanil, Tetrazolylpyrazone, Jinggangmycin, Flutianil, Ipflufenoquin, Quinofumelin, Aminopyrifen, Dipymetitrone, Flufenoxadiazam, Metarylpicoxamid, Fl Any one of umetylsulforim or cintamidine, the weight ratio of active ingredient A to active ingredient (B4+B5) is 1:0.02-100, for example 1:0.02, 1:0.05, 1:0.1, 1:0.5, 1:1, 1:3, 1:5, 1:8, 1:10, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90 or 1:100, preferably 1:0.025-20.

[0070] Typical combinations are shown in Table 1 and Table 2 (the ratios are by weight), but the combinations are not limited thereto.

[0071] Table 1 Binary composition

[0072]

[0073]

[0074]

[0075]

[0076]

[0077] Table 2 Ternary composition

[0078]

[0079]

[0080]

[0081]

[0082]

[0083]

[0084]

[0085]

[0086]

[0087]

[0088]

[0089]

[0090]

[0091]

[0092]

[0093]

[0094]

[0095] In the second aspect, the present invention provides a pharmaceutical preparation, which comprises the pharmaceutical composition containing the pyrazole ether compound as described above and a pesticide-acceptable carrier.

[0096] Preferably, in the pharmaceutical preparation, the weight percentage of the pharmaceutical composition containing the pyrazole ether compound is 0.1-99%, for example, 0.1%, 0.5%, 1%, 3%, 5%, 8%, 10%, 15%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 99%.

[0097] Preferably, the pesticidally acceptable carrier comprises a surfactant.

[0098] In the present invention, the surfactant is an ionic surfactant or a nonionic surfactant.

[0099] Preferably, the surfactant includes any one of a dispersant, a wetting agent, an emulsifier, an antifreeze agent, a thickener, a defoaming agent, a preservative, a stabilizer, a colorant, a filler or a solvent, or a combination of at least two thereof.

[0100] In the present invention, the emulsifier can be dodecylbenzene sulfonate, alkylnaphthalene sulfonate, alkyl sulfonate, alkylphenol polyoxyethylene ether, benzylphenol polyoxyethylene, phenethylphenol polyoxyethylene ether, fatty amine polyoxyethylene ether, etc. Dispersants include lignin sulfonate, alkylphenol polyoxyethylene ether, naphthalenesulfonic acid formaldehyde condensate sodium salt, fatty amine polyoxyethylene ether, fatty acid polyoxyethylene ester, glycerol fatty acid ester polyoxyethylene ether, polycarboxylate, formaldehyde condensate, alkylbenzene sulfonic acid calcium salt, alkylphenol polyoxyethylene ether, etc. Wetting agent is selected from sodium lauryl sulfate, alkylnaphthalene sulfonate, pull open powder BX, polyoxyethylene ether, EO / PO block polyether, fatty alcohol polyoxyethylene ether, fatty alcohol polyoxyethylene ether sulfate, alkyl sodium phosphate, alkylnaphthalene sulfonate, alkylphenol polyoxyethylene sodium sulfate. Emulsifier is selected from dodecylbenzene sulfonate, alkylnaphthalene sulfonate, alkyl sulfonate, alkylphenol polyoxyethylene ether, benzylphenol polyoxyethylene, phenethylphenol polyoxyethylene ether, fatty amine polyoxyethylene ether. The antifreeze agent is selected from ethylene glycol, propylene glycol and glycerol. The thickener is selected from xanthan gum, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl starch, methyl cellulose, sodium starch phosphate, magnesium aluminum silicate and polyvinyl alcohol. The defoamer is selected from silicone oil, silicone compounds, tributyl phosphate, C10-20 saturated fatty acid compounds and polyether defoamers. The preservative is selected from formaldehyde, phenyl salicylate, butyl p-hydroxybenzoate and potassium sorbate. The stabilizer is selected from triphenyl phosphite, epichlorohydrin, epoxy soybean oil and magnesium aluminum silicate. The colorant is selected from azo pigments, titanium oxide and iron oxide.

[0101] Preferably, the pesticide-acceptable carrier comprises a solid carrier and / or a liquid carrier.

[0102] Preferably, the solid carrier includes natural or synthetic clay and silicate, such as natural silica and diatomaceous earth; magnesium silicate, such as talc; magnesium aluminum silicate, such as kaolinite, kaolin, montmorillonite and mica; white carbon black, calcium carbonate, light calcium carbonate; calcium sulfate; limestone; sodium sulfate; amine salts, such as ammonium sulfate, hexamethylenediamine. Liquid carriers include water and organic solvents. When water is used as a solvent or diluent, organic solvents can also be used as adjuvants or antifreeze additives. Suitable organic solvents include aromatic hydrocarbons such as trimethylbenzene, benzene, xylene, toluene, etc.; chlorinated hydrocarbons, such as chlorobenzene, vinyl chloride, chloroform, dichloromethane, etc.; aliphatic hydrocarbons, such as petroleum fractions, cyclohexane, light mineral oil; alcohols, such as isopropanol, butanol, ethylene glycol, glycerol and cyclohexanol, etc.; and their ethers and esters; and ketones, such as acetone, cyclohexanone, dimethylformamide and N-methyl-pyrrolidone.

[0103] In the preparation process of the pharmaceutical preparation described in the present invention, the active component can be mixed with a liquid carrier and / or a solid carrier, and a surfactant (such as an emulsifier, a dispersant, a stabilizer, a wetting agent, etc.) can be added at the same time. Other auxiliary agents (such as an adhesive, a defoaming agent, an antifreeze agent, an oxidant, etc.) can also be added.

[0104] The composition of the present invention can be applied to the diseased plant or its growth medium in the form of a formulation. For example, these chemical formulations can be formulated into soluble solutions (SL), soluble powders (SP), soluble granules (SG), emulsifiable concentrates (EC), wettable powders (WP), emulsions in water (EW), suspensions (SC), dispersible oil suspensions (OD), water dispersible granules (WG), microcapsule suspensions (CS), granules (GR), microemulsions (ME), suspended emulsions (SE), microcapsule suspension-suspension concentrates (ZC), suspended seed coatings (FSC), seed treatment dry powders (DS), seed treatment suspensions (FS), seed treatment soluble powders (SS), seed treatment dispersible powders (WS), seed treatment emulsions (ES), seed treatment liquids (LS), etc.

[0105] Preferably, the dosage form of the pharmaceutical preparation is an aqueous emulsion, a microemulsion, a suspension, a suspoemulsion, a soluble solution, a dispersible solution, an emulsifiable concentrate, a powder, a wettable powder or a dispersible granule.

[0106] Preferably, the weight percentage of the active ingredient in the pharmaceutical preparation is 0.5-90%.

[0107] Preferably, the pharmaceutical preparation is an aqueous emulsion, in which the weight percentage of active ingredient is: 1% to 95%, preferably 5% to 50%; the weight percentage of surfactant is: 1% to 30%, preferably 5% to 20%; and the liquid carrier makes up 100%.

[0108] Preferably, the pharmaceutical preparation is a suspension, in which the weight percentage of active ingredient is 5% to 75%, preferably 10% to 50%, the weight percentage of surfactant is 1% to 40%, preferably 2% to 30%, and the liquid carrier makes up 100%.

[0109] Preferably, the pharmaceutical preparation is a soluble solution, in which the weight percentage of active ingredients is 1% to 95%, preferably 30% to 90%, the weight percentage of surfactant is 1% to 30%, preferably 5% to 20%, and the liquid carrier makes up 100%.

[0110] Preferably, the pharmaceutical preparation is a powder, in which the weight percentage of active ingredient is 0.1% to 10%, preferably 0.5% to 5%, the weight percentage of surfactant is 1% to 30%, preferably 5% to 20%, and the solid carrier makes up 100%.

[0111] Preferably, the pharmaceutical preparation is a wettable powder, in which the weight percentage of active ingredient is 0.5% to 90%, preferably 1% to 80%, the weight percentage of surfactant is 0.5% to 20%, preferably 1% to 15%, and the solid carrier makes up 100%.

[0112] Preferably, the pharmaceutical preparation is a granule, in which

[0113] The weight percentage of active ingredients is 0.1% to 30%, preferably 0.1% to 15%, the weight percentage of surfactant is 1% to 30%, preferably 5% to 20%, and the solid carrier makes up 100%.

[0114] On the other hand, the present invention provides the use of the pharmaceutical composition or pharmaceutical preparation containing the pyrazole ether compound as described above in preventing and controlling plant diseases in agriculture, forestry and horticulture.

[0115] The composition of the present invention has a wide range of applications, and the range of plants or crops to which it is applied mainly includes the following categories:

[0116] Agriculture: wheat, barley, rice, corn, sorghum, potatoes;

[0117] Vegetables: cucumber, loofah, watermelon, melon, pumpkin, hanging melon, spinach, celery, kale, cabbage, gourd, pepper, eggplant, tomato, onion, ginger, garlic, leek, strawberry, lettuce, kidney bean, cowpea, broad bean, radish, carrot, potato, yam;

[0118] Fruit trees: apple, pear, banana, citrus, grape, lychee, mango;

[0119] Cash crops: Oil crops, such as peanuts, soybeans, rapeseed, sunflowers, and sesame; sugar crops, such as beets and sugarcane; other crops, such as tobacco and tea.

[0120] The plants listed above do not limit the scope of use of the pesticide composition.

[0121] The composition of the present invention effectively controls a wide spectrum of plant diseases, including diseases of oomycetes, ascomycetes, basidiomycetes or deuteromycetes; the plants include but are not limited to agriculture, horticulture, vegetables, fruit trees, cash crops, etc.

[0122] Preferably, the plant diseases include but are not limited to:

[0123] Wheat diseases: rust, powdery mildew, fusarium head blight, stem base rot, take-all disease, root rot, sheath blight, and glumem blight;

[0124] Rice diseases: rice blast, rice false smut, sheath blight, and seedling blight;

[0125] Corn diseases: corn rust, corn curvature, corn leaf spot;

[0126] Potato diseases: potato late blight, black leg, and barn scab;

[0127] Vegetable diseases: cucumber downy mildew, cucumber powdery mildew, cucumber anthracnose, cucumber wilt, cucumber gray mold, grape downy mildew, tomato early blight, tomato late blight, watermelon vine blight, pepper root rot;

[0128] Fruit tree diseases: citrus scab, pear black spot, apple rot, banana leaf spot, apple ring rot, mango stem rot;

[0129] Diseases of economic crops: cotton verticillium wilt, cotton wilt, peanut scab, peanut black spot, rapeseed black stem disease, rapeseed sclerotinia rot, soybean rust, and ginseng rust and rot.

[0130] The plants listed above do not limit the scope of use of the pesticide composition.

[0131] In another aspect, the present invention provides use of the pharmaceutical composition containing the pyrazole ether compound as described above in treating seeds of plants, crops or flowers.

[0132] In another aspect, the present invention provides a method for controlling plant diseases, which comprises applying an effective dose of the pharmaceutical composition or pharmaceutical preparation containing the pyrazole ether compound as described above to the plant disease to be controlled or to the medium in which the plant grows.

[0133] Preferably, the effective dose is 10-1000g per hectare, for example 10g, 20g, 50g, 80g, 100g, 120g, 150g, 180g, 200g, 250g, 300g, 350g, 400g, 450g, 500g, 600g, 700g, 800g, 900g or 1000g, preferably 15-600g per hectare.

[0134] Compared with the prior art, the present invention has the following beneficial effects:

[0135] Compared with traditional fungicides, the pharmaceutical composition containing pyrazole ether compounds of the present invention has the following advantages in use:

[0136] (1) The active ingredients A and B in the present invention have a combined synergistic or synergistic effect, the dosage of the agent is greatly reduced compared with a single active ingredient fungicide, and the control effect is significantly improved;

[0137] (2) The control spectrum has been expanded to include a variety of diseases in agriculture, horticulture, vegetables, fruit trees, and cash crops;

[0138] (3) Rotational use or mixed use with drugs of different structural types or different mechanisms of action can effectively prevent or slow down the development of resistance of pathogens to compounds of one type of mechanism of action and delay the development of resistance or drug resistance to drugs. DETAILED DESCRIPTION

[0139] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0140] Formulation Example 1: 50% Compound 6·Chlorothalonil Wettable Powder

[0141]

[0142] Formulation Example 2: 5% Compound 2·Prothioconazole emulsifiable concentrate

[0143]

[0144] Formulation Example 3: 45% Compound 3·Azoxystrobin water dispersible granules

[0145]

[0146] Formulation Example 4: 20% Compound 3·Trifloxystrobin Suspension

[0147]

[0148] Formulation Example 5: 32.5% Compound 2·Prothiostrobin·Trifloxystrobin Suspension Concentrate

[0149]

[0150] Formulation Example 6: 24% Compound 3·Cyclostrobin·Pyraclostrobin Suspension Concentrate

[0151]

[0152] Formulation Example 7: 62.5% Compound 3·trifloxystrobin·tebuconazole water dispersible granules

[0153]

[0154] Formulation Example 8: 28% Compound 3·Fenofoconazole·Azoxystrobin Suspension

[0155]

[0156] Formulation Example 9: 34% Compound 2·fluoxathiapiprolin·Propiconazole emulsifiable concentrate

[0157]

[0158] Formulation Example 10: 42% Compound 3·flupyraclostrobin·trifloxystrobin suspension

[0159]

[0160] Formulation Example 11: 45% Compound 6·Pyraclostrobin·Boscalid Water Dispersible Granules

[0161]

[0162] Formulation Example 12: 50% Compound 6·Fluopyram·Pyrimethanil Suspension Concentrate

[0163]

[0164] Formulation Example 13: 10% Compound 2 emulsifiable concentrate

[0165]

[0166] Formulation Example 14: 20% Compound 3 Suspension

[0167]

[0168] Formulation Example 15: 25% Compound 6 Water Dispersible Granules

[0169]

[0170] Bioassay Example

[0171] Bioassay Example 1: Evaluation of the combination and joint action for controlling rice false smut

[0172] This bioassay embodiment provides a test of the activity of a pharmaceutical composition containing a pyrazole ether compound (the active ingredient A is one of compound 2, compound 3, compound 5, compound 6, and compound 9, and the active ingredient B is one or two of the fungicides in group B1-B5) against rice false smut. The specific contents are as follows:

[0173] (1) Objective: To test the combined effect of the pharmaceutical composition on rice false smut.

[0174] (2) Target: Rice false smut (Ustilaginoidea oryzae), indoor in vitro culture.

[0175] (3) Method: Mycelium growth rate method. The specific steps are carried out in accordance with the agricultural industry standard NY / T 1156.2-2006. The operation is described as follows:

[0176] a) Preparation of pathogens: 5 to 6 days in advance, activate and culture the pathogens on PDA medium for later use;

[0177] b) Preparation of drug solution: Weigh appropriate amounts of active ingredients A and B original drugs, dissolve them in N,N-dimethylformamide (DMF) to prepare a 20000 mg / L mother solution; dilute with a 0.05% Tween-80 aqueous solution to obtain a drug solution of the required dosage; in the test of the combined effect of the drug composition on rice false smut, the two drug solutions were mixed according to the dosage shown in Table 1 to obtain a 50-fold drug solution of the drug composition.

[0178] c) Drug treatment: Under sterile conditions, take 1 mL of the prepared drug solution, mix it with 49 mL of sterile culture medium cooled to about 70°C and shake it evenly, pour equal amounts of the drug-containing culture medium into three culture dishes with a diameter of 9 cm to prepare drug-containing culture media of corresponding series concentrations. Use a sterile special puncher to make pathogen cakes (diameter 5 mm), cut the cakes from the edge of the colony, and use an inoculator to inoculate the cakes in the center of each drug-containing plate, with the mycelium side facing down, cover the dish, and place it in a 25°C incubator for dark culture.

[0179] d) Investigation and statistics: Depending on the growth of pathogens in the blank control dish, when the diameter of the control strain colony grows to 6-8cm (about 5 days after inoculation), start the investigation. Use a caliper to measure the diameter of the colony, and use the cross method to measure the diameter of each colony vertically once. According to the results of the colony diameter investigation, calculate the mycelium growth inhibition rate of each treatment. Calculate according to the following formula:

[0180] Colony growth diameter = colony diameter - cake diameter (0.5) (unit: cm)

[0181] Mycelium growth inhibition rate % = (CK-PT) / CK×100

[0182] Where: CK is the growth diameter of the blank control colony; PT is the growth diameter of the drug-treated colony.

[0183] (4) The evaluation method is as follows:

[0184] Theoretical inhibition rate = 1-(1-inhibition rate of active ingredient A at this dose) (1-inhibition rate of active ingredient B at this dose)

[0185] Synergistic effect = actual inhibition rate - theoretical inhibition rate

[0186] The synergistic effect ≥ 20 indicates significant synergistic effect; 10 ≤ synergistic effect < 20 indicates synergistic effect; -10 ≤ synergistic effect < 10 indicates additive effect;

[0187] A synergistic effect of <-10 indicates antagonism, and the larger the negative value, the greater the degree of antagonism.

[0188] (5) Results: The test results are shown in Table 3.

[0189] Table 3 Combined effects of the drug combination on rice false smut

[0190]

[0191] (6) Conclusion

[0192] In the pharmaceutical composition provided by the present invention, the active ingredient A is one of compound 2, compound 3, compound 5, compound 6 and compound 9; the active ingredient B is one of clofoconazole, hexaconazole and tebuconazole, belonging to group B1; the combination of A+B1 in Table 3 shows synergistic or significant synergistic effect on rice false smut at a ratio of 1:0.05-40.

[0193] In the pharmaceutical composition provided by the present invention, the active ingredient A is one of compound 2 and compound 9; the active ingredient B is (epoxiconazole + validamycin 1:2), epoxiconazole belongs to group B1, and validamycin belongs to group B5, and the pharmaceutical composition A+(B1+B5) shows a synergistic effect on rice false smut at a ratio of 1:0.025-25.

[0194] Bioassay Example 2: Evaluation of combinations and joint actions for controlling watermelon vine blight

[0195] This test example provides a test of the activity of a pharmaceutical composition containing a pyrazole ether compound (the active ingredient A is one of compound 2, compound 3, compound 4, compound 5, compound 6, compound 7, and compound 8, and the active ingredient B is one or two of the fungicides in group B1-B5) against watermelon vine blight. The specific contents are as follows:

[0196] (1) Objective: To test the combined effect of the pharmaceutical composition on watermelon vine blight.

[0197] (2) Target: Watermelon vine blight (Didymella bryoniae), indoor in vitro culture.

[0198] (3) Method: The same test as in Example 1.

[0199] (4) Evaluation method: Same as Example 1.

[0200] (5) Results: The test results are shown in Table 4.

[0201] Table 4 Combined effects of the drug combination on watermelon vine blight

[0202]

[0203] (6) Conclusion

[0204] In the pharmaceutical composition provided by the present invention, the active ingredient A is one of compound 2, compound 6 and compound 8; the active ingredient B is picoxystrobin, belonging to group B2; the combination of A+B2 in Table 4 shows a synergistic effect on watermelon vine blight at 1:0.025-40.

[0205] In the pharmaceutical composition provided by the present invention, the active ingredient A is one of compound 5 and compound 7, the active ingredient B is a compound of two fungicides (fenpropimorph + azoxystrobin 1:1), the fenpropimorph belongs to group B1, and the azoxystrobin belongs to group B2, and the pharmaceutical composition A+(B1+B2) shows a synergistic effect on watermelon vine blight at a ratio of 1:0.05-30.

[0206] In the pharmaceutical composition provided by the present invention, the active ingredient A is one of compound 4 and compound 7, the active ingredient B is a compound of two fungicides (trifloxystrobin + fluopyram 1:1), trifloxystrobin belongs to group B2, and fluopyram belongs to group B3, and the pharmaceutical composition A+(B2+B3) shows a synergistic effect on watermelon vine blight at a ratio of 1:0.04-25.

[0207] In the pharmaceutical composition provided by the present invention, the active ingredient A is one of compound 3 and compound 8, the active ingredient B is a compound of two fungicides (pyraclostrobin + methocarb 1:10), pyraclostrobin belongs to group B2, and methocarb belongs to group B4, and the pharmaceutical composition A+(B2+B4) shows a synergistic effect on watermelon vine blight at a ratio of 1:0.033-20.

[0208] Bioassay Example 3: Evaluation of combinations and joint actions for controlling sclerotinia sclerotiorum of rapeseed

[0209] This bioassay embodiment provides a test of the activity of a pharmaceutical composition containing a pyrazole ether compound (the active ingredient A is one of compound 1, compound 2, compound 3, compound 4, compound 6, compound 7, and compound 9, and the active ingredient B is one or two of the fungicides in group B1-B5) against rapeseed sclerotinia. The specific contents are as follows:

[0210] (1) Objective: To test the combined effects of the pharmaceutical composition on rapeseed sclerotinia rot.

[0211] (2) Target: Sclerotinia sclerotiorum, in vitro culture.

[0212] (3) Method: The same test as in Example 1.

[0213] (4) Evaluation method: Same as Example 1.

[0214] (5) Results: The test results are shown in Table 5.

[0215] Table 5 Combined effects of drug combination on rapeseed sclerotinia

[0216]

[0217] (6) Conclusion

[0218] In the pharmaceutical composition provided by the present invention, the active ingredient A is one of compound 1, compound 2, compound 6, and compound 9, and the active ingredient B is one of isoprofenamide, bixafenamide, and flufenoxam, belonging to group B3. The pharmaceutical composition A+B3 in Table 5 shows a synergistic effect on rapeseed sclerotinia at a ratio of 1:0.05-20.

[0219] In the pharmaceutical composition provided by the present invention, the active ingredient A is one of compound 3 and compound 7, the active ingredient B is a compound of two fungicides (fenpropimorph + fluopicolide 1.5:1), fenpropimorph belongs to group B1, fluopicolide belongs to group B3, and the pharmaceutical composition A+(B1+B3) shows a synergistic effect on rapeseed sclerotinia at a ratio of 1:0.025-40.

[0220] Bioassay Example 4: Evaluation of combinations and combined effects for controlling tomato early blight

[0221] This bioassay embodiment provides a test of the activity of a pharmaceutical composition containing a pyrazole ether compound (the active ingredient A is one of compound 3, compound 4, compound 5, compound 6, compound 7, and compound 8, and the active ingredient B is one or two of the fungicides in group B1-B5) against tomato early blight. The specific contents are as follows:

[0222] (1) Objective: To test the combined effect of the pharmaceutical composition on tomato early blight.

[0223] (2) Target: Tomato early blight (Alternaria solani), indoor in vitro culture.

[0224] (3) Method: The same test as in Example 1.

[0225] (4) Evaluation method: Same as Example 1.

[0226] (5) Results: The test results are shown in Table 6.

[0227] Table 6 Combined effects of drug combinations on tomato early blight

[0228]

[0229] (6) Conclusion

[0230] In the pharmaceutical composition provided by the present invention, the active ingredient A is one of compound 4 and compound 6, the active ingredient B mancozeb belongs to group B4, and the pharmaceutical composition A+B4 exhibits a synergistic effect on tomato early blight at a ratio of 1:0.033-20.

[0231] In the pharmaceutical composition provided by the present invention, the active ingredient A is one of compound 3, compound 4, and compound 7, and the active ingredient B is a compound of two fungicides (fenpropimorph + thiophanate-methyl 1:10), fenpropimorph belongs to group B1, and thiophanate-methyl belongs to group B4, and the pharmaceutical composition A+(B1+B4) shows a synergistic effect on tomato early blight at a ratio of 1:0.025-64.

[0232] In the pharmaceutical composition provided by the present invention, the active ingredient A is one of compound 5 and compound 7, the active ingredient B is a compound of two fungicides (flupyraclostrobin + propineb 1:2), flupyraclostrobin belongs to group B3, and propineb belongs to group B4, and the pharmaceutical composition A+(B3+B4) shows a synergistic effect on tomato early blight at a ratio of 1:0.05-40.

[0233] In the pharmaceutical composition provided by the present invention, the active ingredient A is one of compound 3 and compound 8, the active ingredient B is a compound of two fungicides (fluopyram + pyrimethanil 1:3), fluopyram belongs to group B3, pyrimethanil belongs to group B5, and the pharmaceutical composition A+(B3+B5) shows a synergistic effect on tomato early blight at a ratio of 1:0.025-40.

[0234] Bioassay Example 5: Evaluation of combinations and joint effects for controlling apple leaf spot disease

[0235] This test example provides a test of the activity of a pharmaceutical composition containing a pyrazole ether compound (the active ingredient A is one of compound 2, compound 3, compound 6, compound 8, and compound 9, and the active ingredient B is one or two of the fungicides in group B1-B5) against apple leaf spot disease. The specific contents are as follows:

[0236] (1) Objective: To test the combined effect of the pharmaceutical composition on apple leaf spot disease.

[0237] (2) Target: Apple leaf spot disease (Alternaria mali), indoor in vitro culture.

[0238] (3) Method: The same test as in Example 1.

[0239] (4) Evaluation method: Same as Example 1.

[0240] (5) Results: The test results are shown in Table 7.

[0241] Table 7 Combined effects of the drug combination on apple leaf spot disease

[0242]

[0243] (6) Conclusion

[0244] In the pharmaceutical composition provided by the present invention, the active ingredient A is one of compound 2, compound 6, compound 8 and compound 9, the active ingredient B is compounded with one of cyprodinil and iprodione, cyprodinil and iprodione belong to group B5, and the pharmaceutical composition A+B5 shows a synergistic effect on apple leaf spot disease at a ratio of 1:0.033-40.

[0245] In the pharmaceutical composition provided by the present invention, the active ingredient A is one of compound 3 and compound 8, the active ingredient B is a compound of two fungicides (mancozeb+carbendazim 1:1), mancozeb belongs to group B4, and carbendazim belongs to group B5, and the pharmaceutical composition A+(B4+B5) shows a synergistic effect on apple leaf spot disease at a ratio of 1:0.025-20.

[0246] Bioassay Example 6: Evaluation of combinations and joint actions for controlling wheat powdery mildew

[0247] This test example provides a test of the activity of a pharmaceutical composition containing a pyrazole ether compound (the active ingredient A is compound 3, and the active ingredient B is prothioconazole) against wheat powdery mildew. The specific contents are as follows:

[0248] (1) Objective: To test the combined effect of the pharmaceutical composition on wheat powdery mildew.

[0249] (2) Target: Wheat powdery mildew (Blumeria graminis), preserved in living culture.

[0250] (3) Method: Pot culture method (protective activity); the specific steps were carried out in accordance with the agricultural industry standard NY / T 1156.4-2006.

[0251] The operation is described as follows:

[0252] a) Preparation of drug solution: Weigh appropriate amounts of active ingredients A and B original drugs, dissolve them in N,N-dimethylformamide (DMF) to prepare a 20000 mg / L stock solution; dilute with a 0.05% Tween-80 aqueous solution to obtain a drug solution of the required dosage; mix the two drug solutions according to the dosage shown in Table 8 to obtain the test drug solution of the drug composition.

[0253] b) Chemical treatment: Use a throat sprayer to evenly spray the chemical on the wheat leaves at the one-leaf and one-heart stage, repeat 3 times for each treatment, and place them indoors to dry naturally after spraying. 24 hours after chemical treatment, shake off the wheat powdery mildew spores produced about 10 days after inoculation evenly on the wheat leaves after the chemical treatment.

[0254] c) Survey and Statistics:

[0255] Ten days after inoculation of spores, an investigation was conducted when the disease of the control group stabilized.

[0256] Investigate the disease level of the first leaf at the stem base of all plants in each pot.

[0257] The original data of the survey were input into Microsoft Excel, and the disease index and control effect of each treatment were calculated using formulas.

[0258] The efficacy is calculated according to the following formula:

[0259]

[0260]

[0261] Where:

[0262] CK- average disease index of clean water control;

[0263] PT - average disease index after drug treatment.

[0264] (4) Evaluation method: DPS statistical software was used to perform regression analysis on the logarithmic values ​​of the concentrations of each single agent and different ratios of the mixture and the probability values ​​of the corresponding protective efficacy to calculate the EC 50 Refer to NY / T 1156.6-2006 and evaluate by co-toxicity coefficient.

[0265] The co-toxicity coefficient (CTC value) of the mixture is calculated according to the following formula:

[0266]

[0267] Where: ATI—actual toxicity index of the mixture;

[0268] S—EC of standard agent 50 , the unit is milligrams per liter (mg / L);

[0269] M—EC of the mixture 50 , the unit is milligrams per liter (mg / L).

[0270] TTI=TI A ×P A +TI B ×P B

[0271] Where: TTI—theoretical toxicity index of mixture;

[0272] TI A —A. Toxicity index of the agent;

[0273] P A —The percentage of agent A in the mixture, in percentage (%);

[0274] TI B —B Agent toxicity index;

[0275] P B —The percentage of agent B in the mixture, in percentage (%).

[0276]

[0277] In the formula: CTC is the co-toxicity coefficient; ATI is the measured toxicity index of the mixture; TTI is the theoretical toxicity index of the mixture.

[0278] A co-toxicity coefficient (CTC) ≥ 120 indicates a synergistic effect; CTC ≤ 80 indicates an antagonistic effect; and 80 < CTC < 120 indicates an additive effect.

[0279] (5) Results: The test results are shown in Table 8.

[0280] Table 8 Combined effects of drug combination on wheat powdery mildew

[0281]

[0282] (6) Conclusion

[0283] In the pharmaceutical composition provided by the present invention, the active ingredient A is compound 3, and the active ingredient B is prothioconazole. The pharmaceutical composition belongs to an A+B1 combination. Within the range of a ratio of 1:0.05-40, the co-toxicity coefficient to wheat powdery mildew is 191.27-254.17, all of which are greater than 120, and all show a synergistic effect.

[0284] Bioassay Example 7: Evaluation of combinations and joint actions for controlling rice blast

[0285] This bioassay embodiment provides a pharmaceutical composition containing a pyrazole ether compound (the active ingredient A is compound 4, and the active ingredient B is pyraclostrobin + pyraclostrobin 2:1), and the activity test on rice blast is as follows:

[0286] (1) Objective: To test the combined effect of the pharmaceutical composition on rice blast.

[0287] (2) Target: Rice blast (Pyricularia oryae), in vitro culture.

[0288] (3) Method: The same test as in Example 1.

[0289] (4) Evaluation method: Same as Example 6.

[0290] (5) Results: The test results are shown in Table 9.

[0291] Table 9 Combined effects of the drug combination on rice blast

[0292]

[0293]

[0294] (6) Conclusion

[0295] In the pharmaceutical composition provided by the present invention, the active ingredient A is compound 4, and the active ingredient B is a compound of two fungicides (pyraclostrobin + blasticide 2:1), pyraclostrobin belongs to group B2, and blasticide belongs to group B5. The pharmaceutical composition belongs to the combination of A+(B2+B5), and within the range of a ratio of 1:0.05-20, the co-toxicity coefficient to rice blast pathogen is 123.00-215.23, all greater than 120, showing a synergistic effect. Bioassay Example 8: Evaluation of the combination and joint action for preventing and controlling corn rust

[0296] This bioassay example provides a pharmaceutical composition containing a pyrazole ether compound (the active ingredient A is compound 2, and the active ingredient B is bixafen), and the activity test against corn rust is as follows:

[0297] (1) Purpose: To test the combined effects of the pharmaceutical composition on corn rust.

[0298] (2) Target: Corn rust (Puccinia sorghi), preserved in vivo.

[0299] (3) Methods: The preparation, application and investigation methods are the same as those in Example 6 of the bioassay.

[0300] 24h after spraying, 1*10 5 The spore solution of 100 / mL was inoculated on corn leaves.

[0301] (4) Evaluation method: Same as Example 6.

[0302] (5) Results: The test results are shown in Table 10.

[0303] Table 10 Combined effects of drug combinations on corn rust

[0304]

[0305] (6) Conclusion

[0306] In the pharmaceutical composition provided by the present invention, the active ingredient A is compound 2, and the active ingredient B is bixafen. The pharmaceutical composition belongs to the A+B3 combination. Within the ratio range of 1:0.025-40, the co-toxicity coefficient to corn rust is 128.86-284.42, all of which are greater than 120, showing a synergistic effect.

[0307] Bioassay Example 9: Evaluation of Combinations and Joint Actions for Controlling Pepper Anthracnose

[0308] This bioassay example provides an activity test of a pharmaceutical composition containing a pyrazole ether compound (the active ingredient A is compound 6, and the active ingredient B is dicyanoanthraquinone) against pepper anthrax. The specific contents are as follows:

[0309] (1) Objective: To test the combined effect of the pharmaceutical composition on pepper anthracnose.

[0310] (2) Target: Pepper anthracnose (Colletotrichum capsici), in vitro culture.

[0311] (3) Method: The same test as in Example 1.

[0312] (4) Evaluation method: Same as Example 6.

[0313] (5) Results: The test results are shown in Table 11.

[0314] Table 11 Combined effects of the drug combination on pepper anthracnose

[0315]

[0316] (6) Conclusion

[0317] In the pharmaceutical composition provided by the present invention, the active ingredient A is compound 6, and the active ingredient B is dicyanoanthraquinone. The pharmaceutical composition belongs to the A+B4 combination. Within the ratio range of 1:0.05-20, the co-toxicity coefficient to pepper anthracnose is 126.45-297.63, all of which are greater than 120, showing a synergistic effect.

[0318] Bioassay Example 10: Combination for controlling wheat scab and field efficacy

[0319] This test example provides a field plot efficacy test of the pharmaceutical compositions in Formulation Example 2, Formulation Example 5, Formulation Example 9 and the 10% emulsifiable concentrate of Compound 2 in Formulation Example 13 for controlling wheat scab, and the specific contents are as follows:

[0320] (1) Objective: To test and evaluate the field efficacy of the drug combination in controlling wheat fusarium head blight, using 25% cyanothiocarb SC, a commonly used drug on the market, as a control.

[0321] (2) Test agents: 5% Compound 2·prothioconazole emulsifiable concentrate, 32.5% Compound 2·prothioconazole·trifloxystrobin SC, 34% Compound 2·fluoxathiocarb·propiconazole emulsifiable concentrate, 10% Compound 2 emulsifiable concentrate.

[0322] (3) Target: Wheat fusarium graminearum, which occurs naturally in the field. The test site is located in Jinjiagang Village, Baibu Town, Haiyan County, Zhejiang Province.

[0323] (4) Time: April-May 2023.

[0324] (5) Method: Spray method. Each agent was treated in 3 replicate plots; each plot had an area of ​​20 m 2 , use ZBDP-16 backpack electric sprayer to spray evenly twice, the first application is at the early stage of wheat flowering, the second application is 7 days later, and the results are investigated 21 days after the second application. The investigation method refers to the industry standard NY / T 1464.15-2007 "Guidelines for Field Efficacy Tests of Pesticides Part 15: Fungicide Control of Wheat Fusarium Head Blight", the investigation data are statistically analyzed, and the control effect is calculated.

[0325] (6) Results: The test results are shown in Table 12.

[0326] Table 12 Field efficacy of pesticides against wheat scab

[0327]

[0328] In the above combination agent, the numbers in brackets represent the mass percentage content of each component, for example, 5% compound 2·prothioconazole emulsifiable concentrate (3+2) means that the content of compound 2 is 3% and the content of prothioconazole is 2%.

[0329] (7) Conclusion

[0330] In the pharmaceutical composition provided by the present invention, 5% compound 2·prothioconazole emulsifiable concentrate belongs to the A+B1 combination, and the ratio is 1:0.67. Compared with a single agent (10% compound 2 emulsifiable concentrate), at the same dosage of 16 gai / mu, the control effect of the composition (87.25%) is significantly higher than the control effect of the single agent by 60.01% (the control effect is increased by 27.24%); the control effect of the composition at 16 gai / mu is slightly better than the control effect of the compound at 32 gai / mu (the control effect is increased by 8.35%), and is also better than the control effect of the control agent cyanothiocarb at 40 gai / mu (the control effect is increased by 12.70%).

[0331] In the pharmaceutical composition provided by the present invention, 32.5% compound 2·prothiostrobin·trifloxystrobin suspension belongs to the combination of A+(B1+B2), and the ratio is 1:(0.54:0.46). Compared with a single agent (10% compound 2 emulsifiable concentrate), at the same dosage of 16 gai / mu, the control effect of the composition (86.71%) is significantly higher than the control effect of the single agent of 60.01% (the control effect increases by 26.70%). The control effect of the composition at 16 gai / mu is slightly better than the control effect of the compound at 32 gai / mu (the control effect increases by 7.81%), and is also better than the control effect of the control agent cyanothiostrobin at 40 gai / mu (the control effect increases by 12.16%).

[0332] In the pharmaceutical composition provided by the present invention, 34% compound 2·flutrifloxystrobin·propiconazole emulsifiable concentrate belongs to the combination of A+(B1+B3), and the ratio is 1:(0.47:0.53). Compared with a single agent (10% compound 2 emulsifiable concentrate), at the same dosage of 16 gai / mu, the control effect of the composition (86.23%) is significantly higher than the control effect of the single agent by 60.01% (the control effect increases by 26.22%). The control effect of the composition at 16 gai / mu is slightly better than the control effect of the compound at 32 gai / mu (the control effect increases by 7.33%), and is also better than the control effect of the control agent cyanothiocarb at 40 gai / mu (the control effect increases by 11.68%).

[0333] Unexpectedly, wheat powdery mildew also occurred in the test plots at the same time as wheat fusarium head blight occurred during the test period, and the three combinations containing compound 2 all showed excellent control effects on wheat powdery mildew. Similarly, the control effects of the three combinations were better than those of a single agent.

[0334] In this embodiment, the composition has improved prevention effect, reduced the dosage of effective ingredients, expanded the bactericidal spectrum, and has good development potential compared with the control agent.

[0335] Bioassay Example 11: Combination and field efficacy for controlling cucumber target spot disease

[0336] This test example provides a field plot efficacy test of the pharmaceutical composition in Formulation Example 4, Formulation Example 6, and Formulation Example 10 for preventing and treating cucumber target spot disease. The specific contents are as follows:

[0337] (1) Objective: To test and evaluate the field effect of the drug combination on the control of cucumber target spot disease, using 43% fluopicolide-trifloxystrobin SC, a commonly used drug on the market, as a control.

[0338] (2) Test agents: 20% compound 3·trifloxystrobin suspension concentrate, 24% compound 3·fluopyrabone·pyraclostrobin suspension concentrate, 42% compound 3·fluopyrabone·trifloxystrobin suspension concentrate, 20% compound 3 suspension concentrate.

[0339] (3) Target: Cucumber target spot disease (Corynespora cassiicola). The test site was located in a cucumber greenhouse in Houyuan Village, Yuantai Town, Wafangdian City, Dalian City, Liaoning Province. The cucumber variety was Xintai Micir. Cucumber target spot disease occurred sporadically during the first application of the pesticide.

[0340] (4) Time: October to November 2022.

[0341] (5) Method: Spray method. Each agent was treated in 3 replicate plots; each plot had an area of ​​12 m 2 , a ZBDP-16 backpack electric sprayer was used to spray evenly twice, with an interval of 7 days between the two applications. The results were investigated 7 days and 14 days after the second application. The investigation method referred to the national standard GB / T17980.27-2000 "Guidelines for Field Efficacy Tests of Pesticides (I): Fungicide Control of Vegetable Leaf Spot", and the investigation data was statistically analyzed to calculate the control effect.

[0342] (6) Results: The test results are shown in Table 13.

[0343] Table 13 Field efficacy of pesticides against cucumber target spot disease

[0344]

[0345] Note: In the above combination agent, the numbers in brackets represent the mass percentage content of each component, for example, 20% compound 3·trifloxystrobin suspension (10+10) means that the content of compound 3 is 10% and the content of trifloxystrobin is 10%.

[0346] (7) Conclusion

[0347] In the pharmaceutical composition provided by the present invention, 20% compound 3·trifloxystrobin suspension (10+10) belongs to the A+B2 combination, the ratio is 1:1, and compared with a single agent (10% compound 3 suspension), at the same dosage of 150 mg / L, based on the last investigated prevention effect, the prevention effect of the composition (87.65%) is significantly higher than the prevention effect of the single agent of 68.76% (the prevention effect increases by 18.89%); the prevention effect of the composition at 150 mg / L is slightly better than the prevention effect of compound 3 at 200 mg / L of 78.36% (the prevention effect increases by 9.29%), and is also better than the prevention effect of the control agent 43% fluopicolide·trifloxystrobin SC at 200 mg / L of 70.35% (the prevention effect increases by 17.30%).

[0348] In the pharmaceutical composition provided by the present invention, 42% compound 3·flupyraclostrobin·trifloxystrobin suspension concentrate (18+12+12) belongs to the combination of A+(B2+B3), and the ratio is 1:(0.67+0.67). Compared with a single agent (10% compound 3 suspension concentrate), at the same dosage of 150 mg / L, based on the last investigated prevention effect, the prevention effect of the composition (80.12%) is significantly higher than the prevention effect of the single agent of 68.76% (the prevention effect increases by 11.36%); the prevention effect of the composition at 150 mg / L is equivalent to the prevention effect of 78.36% of compound 3 at 200 mg / L (the prevention effect increases by 1.76%), and is better than the prevention effect of 70.35% of the control agent 43% flupyraclostrobin·trifloxystrobin SC at 200 mg / L (the prevention effect increases by 10.28%).

[0349] In the pharmaceutical composition provided by the present invention, 24% compound 3·fluanidazole·pyraclostrobin suspension (8+8+8) belongs to the combination of A+(B1+B2), and the ratio is 1:(1+1). Compared with a single agent (10% compound 3 suspension), at the same dosage of 150 mg / L, based on the last investigated prevention effect, the prevention effect of the composition (81.20%) is significantly higher than the prevention effect of the single agent by 68.76% (the prevention effect increases by 12.44%); the prevention effect of the composition at 150 mg / L is equivalent to the prevention effect of compound 3 at 200 mg / L, which is 78.36% (the prevention effect increases by 2.84%), and is better than the prevention effect of the control agent 43% fluanidazole·trifloxystrobin SC at 200 mg / L, which is 70.35% (the prevention effect increases by 10.85%).

[0350] In this example, the composition has improved control effect and reduced the dosage of the active ingredient; compared with the control agent, it has great development potential.

[0351] This test example provides a field plot efficacy test of the pharmaceutical composition in Formulation Example 1, Formulation Example 11, and Formulation Example 12 for preventing and controlling tomato gray mold, and the specific contents are as follows:

[0352] (1) Objective: To test and evaluate the field efficacy of the drug combination in controlling tomato gray mold using 50% procymidone WP, a commonly used drug in the market, as a control.

[0353] (2) Test agents: 50% compound 6·thiophanate-methyl wettable powder, 45% compound 6·pyraclostrobin·boscalid water dispersible granules, 50% compound 6·fluopyram·pyrimethanil suspension concentrate, 25% compound 6 water dispersible granules.

[0354] (3) Target: Tomato gray mold (Botrytis cinerea). The test site was located in a tomato greenhouse in Xinggongshan Village, Dongpu Town, Shaoxing City, Zhejiang Province. The tomato variety was Hezuo 903. When the pesticide was first applied, sporadic occurrences of tomato gray mold occurred.

[0355] (4) Time: November to December 2022.

[0356] (5) Method: Spray method. Each agent was treated in 3 replicate plots; each plot had an area of ​​12 m 2 , use ZBDP-16 backpack electric sprayer to spray evenly twice, with an interval of 7 days between the two applications. The results were investigated 14 days after the second application. The investigation method referred to the national standard GB / T17980.28-2000 "Guidelines for Field Efficacy Tests of Pesticides (I) Fungicides for Control of Vegetable Gray Mold". The investigation data were statistically analyzed and the control effect was calculated.

[0357] (6) Results: The test results are shown in Table 14.

[0358] Table 14 Field efficacy of pesticides against tomato gray mold

[0359] Name of the test drug or composition Active ingredient dosage (mg / L) Disease index Control effect% 50% Compound 6·Thiophanate-methyl wettable powder (10+40) 1000 6.14 84.87 50% Compound 6·Fluopyram·Pyrimethanil Suspension Concentrate (14+9+27) 300 7.08 82.55 45% Compound 6·Pyraclostrobin·Boscalid water dispersible granules (15+10+20) 300 7.27 82.08 25% Compound 6 Water Dispersible Granules 300 9.63 76.27 75% Thiophanate WP 2000 9.04 77.72 50% Procymidone WP 1000 20.12 50.42 Clear water control / 40.58 /

[0360] Note: In the above combination agent, the numbers in brackets represent the mass percentage content of each component, for example, 50% compound 6·thiophanate-methyl wettable powder (10+40) means that the content of compound 5 is 10% and the content of thiophanate-methyl is 40%.

[0361] (7) Conclusion

[0362] In the pharmaceutical composition provided by the present invention, 50% of compound 6·thiophanate-methyl wettable powder (10+40) belongs to the A+B4 combination, the ratio is 1:4, and at the same dosage of 1000 mg / L, compared with the control agent procymidone, the protective effect of the composition (84.87%) is significantly higher than the protective effect of the control agent 50.42% (the protective effect increases by 34.45%); the protective effect of the composition at 1000 mg / L is slightly better than the protective effect of 77.72% of thiophanate-methyl at 2000 mg / L (the protective effect increases by 7.15%).

[0363] In the pharmaceutical composition provided by the present invention, 50% compound 6·fluopyram·pyrimidine suspension (14+9+27) belongs to the A+(B3+B5) combination, and the ratio is 1:(0.64+1.93). Compared with a single dose (25% compound 6 water dispersible granules), at the same dose of 300 mg / L, the protective effect of the composition (82.55%) is higher than the protective effect of the single dose by 76.27% (the protective effect increases by 6.28%); compared with the control agent carbendazim, the protective effect of the composition at a dose of 300 mg / L is significantly higher than the protective effect of the control agent at a dose of 1000 mg / L by 50.42% (the protective effect increases by 32.13%).

[0364] In the pharmaceutical composition provided by the present invention, 45% compound 6·pyraclostrobin·boscalid water-dispersible granules (15+10+20) belong to the A+(B2+B3) combination, with a ratio of 1:(0.67+1.33). Compared with a single agent (25% compound 6 water-dispersible granules), at the same dosage of 300 mg / L, the protective effect of the composition (82.08%) is higher than that of the single agent by 76.27% (the protective effect increases by 5.81%); compared with the control agent procymidone, the protective effect of the composition at a dosage of 300 mg / L is significantly higher than that of the control agent at a dosage of 1000 mg / L by 50.42% (the protective effect increases by 31.66%).

[0365] In this embodiment, the composition has improved prevention effect and reduced the dosage of effective ingredients; compared with the control agent, it has good development potential.

[0366] Bioassay Example 13: Combination for controlling rice blast and field efficacy

[0367] This test example provides field plot efficacy tests of the pharmaceutical compositions in Formulation Example 3, Formulation Example 7, and Formulation Example 8 for controlling rice blast, and the specific contents are as follows:

[0368] (1) Objective: To test and evaluate the field efficacy of the pharmaceutical composition for controlling rice blast using 75% tricyclazole WP, a commonly used agent in the market, as a control.

[0369] (2) Test agents: 45% Compound 3·azoxystrobin water dispersible granules, 62.5% Compound 3·trifloxystrobin·tebuconazole water dispersible granules, 28% Compound 3·fenofoconazole·azoxystrobin suspension, 20% Compound 3 suspension.

[0370] (3) Target: Rice blast (Pyricularia oryzae), panicle blast, naturally occurring in the field. The test site was located in Chenjia Village, Xujia Town, Nancheng County, Fuzhou City, Jiangxi Province.

[0371] (4) Time: June-July 2021.

[0372] (5) Method: Spray method. Each agent was treated in 3 replicate plots; each plot had an area of ​​20 m 2 , use ZBDP-16 backpack electric sprayer to spray evenly twice, the first time 3 to 5 days before rice burst, the second time at the heading stage, and the result investigation 18 days after the second application. The investigation method refers to the national standard GB / T 17980.19-2000 "Guidelines for Field Efficacy Tests of Pesticides (I) Fungicides for Control of Rice Leaf Diseases", and the investigation data are statistically analyzed to calculate the control effect.

[0373] (6) Results: The test results are shown in Table 15.

[0374] Table 15 Field efficacy of pesticides against rice blast

[0375] Name of the test drug or composition Active ingredient dosage (gai / mu) Disease index Control effect% 45% Compound 3·Azoxystrobin water dispersible granules (5+40) 20 2.38 95.86 62.5% Compound 3·Trifloxystrobin·Tebuconazole water dispersible granules (25+12.5+25) 20 2.74 95.24 28% Compound 3·Fenfenconazole·Azoxystrobin SC (14+6+8) 20 3.15 94.53 20% Compound 3 Suspension 20 16.57 71.21 75% Tricyclazole WP 30 10.87 81.11 Clear water control / 57.55 /

[0376] Note: In the above combination agent, the numbers in brackets represent the mass percentage content of each component, for example, 45% compound 3·azoxystrobin water dispersible granules (5+40) means that the content of compound 3 is 5% and the content of azoxystrobin is 40%.

[0377] (7) Conclusion

[0378] In the pharmaceutical composition provided by the present invention, 45% compound 3·mystrobin water dispersible granules (5+40) belong to the A+B2 combination, with a ratio of 1:8. At the same dosage of 20 gai / mu, compared with compound 3, the control effect of the composition is 95.86%, which is significantly better than the control effect of a single dose of compound 3 of 71.21% (the control effect is increased by 24.65%), and is also better than the control effect of the control agent tricyclazole at 30 gai / mu of 81.11% (the control effect is increased by 14.75%).

[0379] In the pharmaceutical composition provided by the present invention, 62.5% of compound 3·trifloxystrobin·tebuconazole water dispersible granules (25+12.5+25) belong to the A+(B1+B2) combination, with a ratio of 1:(0.5+1). At the same dosage of 20 gai / mu, compared with compound 3, the control efficacy of the composition is 95.24%, which is significantly better than the control efficacy of a single dose of compound 3 of 71.21% (the control efficacy is increased by 24.03%), and is also better than the control efficacy of the control agent tricyclazole of 81.11% at 30 gai / mu (the control efficacy is increased by 14.13%).

[0380] In the pharmaceutical composition provided by the present invention, 28% of compound 3·fenpropimorph·myclobutanil suspension (14+6+8) belongs to the combination of A+(B1+B2), and the ratio is 1:(0.43+0.57). At the same dosage of 20 gai / mu, compared with compound 3, the control effect of the composition is 94.53%, which is significantly better than the control effect of a single dose of compound 3 of 71.21% (the control effect is increased by 23.32%), and is also better than the control effect of the control agent tricyclazole at 30 gai / mu of 81.11% (the control effect is increased by 13.42%).

[0381] In this embodiment, the composition has improved prevention effect and reduced the dosage of effective ingredients; compared with the control agent, it has good development potential.

[0382] The applicant declares that the present invention illustrates the pharmaceutical composition containing pyrazole ether compounds and its application through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

Claims

1. A pharmaceutical composition containing a pyrazole ether compound, characterized in that: The pharmaceutical composition comprises an active ingredient A and an active ingredient B, wherein the active ingredient A is a pyrazole ether compound having a structure shown in Formula I: R1 is selected from hydrogen, halogen, cyano, nitro, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, heptafluoroisopropyl, methoxy, difluoromethoxy or trifluoromethoxy; R2 is selected from halogen, methyl, difluoromethyl, trifluoromethyl, methoxy, difluoromethoxy or trifluoromethoxy; R3 is selected from hydrogen, halogen, methyl, difluoromethyl or trifluoromethyl; n represents an integer from 0 to 5; The active ingredient B is selected from any one or a combination of at least two of azole fungicides, mitochondrial electron transport chain complex III inhibitor fungicides, SDHI fungicides, multi-site contact fungicides or other fungicides.

2. The pharmaceutical composition containing a pyrazole ether compound according to claim 1, characterized in that: The active ingredient A is any one of the following compounds:

3. The pharmaceutical composition containing a pyrazole ether compound according to claim 2, characterized in that: The active ingredient A is selected from compound 2, compound 3 or compound 6.

4. The pharmaceutical composition containing a pyrazole ether compound according to any one of claims 1 to 3, characterized in that: The active ingredient B is any one or a combination of at least two of the fungicides B1 to B5 described below. (B1) azole fungicides, including pentoconazole, ethoconazole, ipiconazole, bifenthrin, oxadiazole, cyproconazole, fenpropimorph, diniconazole, epoxiconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imipenem, clofoconazole, metconazole, myclobutanil, penconazole, propiconazole, silyconazole, tebuconazole, tetrafluconazole, triadimefon, triadimenol, trimethoprim-butyl, prothioconazole, Fluoxytioconazole, imazalil, oxadiazole, pyraclostrobin, prochloraz, trifloxystrobin, triamcinol, trimethoprim-butyl, prochloraz, triflumizole, triamcinol, trifloxystrobin ... (B2) mitochondrial electron transport chain complex III inhibitors, including pyraclostrobin, fluoxastrobin, azoxystrobin, pyraclostrobin, syringosterone, enoxastrobin, flutoxifen, picoxystrobin, pyraclostrobin, pyraclostrobin, chlorpyrifos, oxadix, oxazolidinone, pyraclostrobin, enoxastrobin, chlorpyrifos, famoxadone, pyraclostrobin, enoxastrobin, fenoxystrobin, oxazolidinone, pyraclostrobin, fenoxystrobin, mandestrobin; (B3) SDHI fungicides, including flutolanil, mefenamic acid, isopyram, fluopyram, triflupyramide, fenfuram, oxycarboxin, thiofuran, benzovinflumazole, bixafen, fluinoxadone, fluopyram, fluopyram, furopyram, inpyrfluxam, pyraclostrobin, fluopyram, penthiopyrad, flutolanil, isoflucypram, fluopyram, boscalid, furamide, isoflucypram, bixafen, fenoxadone or pyrapropoyne; (B4) Multi-site contact fungicides, including: copper preparations, sulfur, chlorothalonil, ferram, mancozeb, maneb, methocarb, propineb, thiram, zinc thiazole, mancozeb, thiram, captan, captafol, folpet, benzylfluanid, tolylfluanid, biguanide salts, fluoroimide, dicyanoanthraquinone, mancozeb, and sulfamethoxazole; (B5) Other fungicides: bensulfuron, bensulfuron-M, furalaxyl, metalaxyl, metalaxyl-M, furamide, oxadixyl, pyrimidine sulfonate, dimethoate, pyrimidine, octhiocarb, oxadixyl, quinacridone, ipflufenoquin; benomyl, carbendazim, oxadixyl, thiophanate-methyl, thiophanate-methyl, ethotripsy, benomyl, pencuron, fluopyram, fluopyram, cyanothiocarb, benomyl, Fyriofenone, Fluopyram, Tetracycline, Cyazofamid, Indazole Sulfonamide, Fenpicoxamid, Pyridine, Nizostrobin, Fluazinam, Triphenyltin Acetate, Triphenyltin Chloride, Triphenyltin Hydroxide, Silthiopyrad, Azopyrad; Cyprodinil, Cyprodinil, Cyprodinil, Methionine, Kasugamycin, Streptomycin, Oxytetracycline, Phenoxyquin, Propoxyquin, Fenzoline, Flutoxil, Ethiocyanate, Sclerotin, Iprodione, Procymidone, Vinclozolin, Rice Blast, Difenothioate, Isothioate, Biphenyl, Dimethoate, Chlornitril, Pentachloronitrobenzene, Tetrachloronitrobenzene, Cyproconazole, Cyproconazole, Iodocarb, Natamycin, Fluoxapiproline, Dimethylmorpholine, Dodecamorpholine, Tridecamorpholine, Butylmorpholine, Fenpropidin, Powdery Mildew Ling, spiroxafil, amine pyraclostrobin, cyclamoxadone, naftifine, terbinafine, polyoxin, dimethomorph, flumorph, butylpyraclostrobin, dimethomorph, benzathiapyr, valerian, valerian; tetrachlorophthalide, pyroquilone, tricyclazole, dichlorocyanamide, cyclopropane amide, rice blastamide, Tolprocarb, activated ester, allylbenzazole, thiazolamide, isothiazolamide, kelp polysaccharide, Reynoutria sachalinensis (a plant extract), P6 Bacillus mycoides (bacteria), Cell walls of Saccharomyces cerevisiae Strain LAS117 (fungus), fosetyl-aluminum, phosphorous acid, cymoxanil, chloranil, imidazobactam, sulfaquinoxaline, pyraclostrobin, cyfluanid, pyrimidine, tetrazolylpyram, isobutylethoxyquin, jinggangmycin, dodecacyclic morpholine, Flutianil, Ipflufenoquin, Quinofumelin, Aminopyrifen, dipymetitrone, Flufenoxadiazam, Metarylpicoxamid, Flumetylsulforim, or cintamidine; Preferably, the active ingredient B is selected from any one or a combination of at least two of the following groups B1-B5 fungicides: (B1) Azoles fungicides, including: cyproconazole, fenpropimorph, epoxiconazole, hexaconazole, clofoconazole, metconazole, myclobutanil, propiconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triclosan, prothioconazole, fluoxytioconazole, imazalil, prochloraz or pyraclostrobin; (B2) mitochondrial electron transport chain complex III inhibitors, including fluoxastrobin, azoxystrobin, pyraclostrobin, syringosterone, enoxastrobin, picoxystrobin, pyraclostrobin, oxazolidinone, chlorpyrifos, famoxadone, oxazolidinone, enoxamyl, fenoxystrobin, oxazolidinone, oxazolidinone, fenoxamyl, fenoxystrobin, oxazolidinone, fenoxamyl, fenoxamyl, or mandestrobin; (B3) SDHI fungicides, including: Flutolanil, Isothiopyrad, Fluopyram, Triflupyridam, Fenfuram, Thifuroxamide, Benzovinflumazole, Bixafen, Fluinoxadone, Fluopyram, Furapyram, Inpyrfluxam, Pyrafenib, Fluopyram, Penthiopyrad, Fluopyram, Isoflucypram, Fluopyram, Boscalid, Mefuroxamide, Isoflupyram, Bixafen, Fenfuram or Pyrapropoyne; (B4) Multi-site contact fungicides, the group consisting of: copper preparations, sulfur, thiophanate-methyl, mancozeb, propineb, thiram, zinc thiabendate or captan; (B5) Other fungicides: Metalaxyl, Metalaxyl-M, Oxadixyl, Ethylpyrimidine Sulfonate, Ethylpyrimidine, Quinclorac, Benomyl, Carbendazim, Thiabendazole, Thiophanate, Thiophanate-methyl, Dithiocarb, Fluopyram, Fluopyram, Cyanocobacteramide, Cyanoprolin, Metraconazole, Pyriofenone, Fluopyram, Tetracycline, Cyazofamid, Indazole Sulfonamide, Fenpicoxamid, Pyridine Bactamide, Nibenstrobin, Fluazinam, Sithiopyram, Cyprodinil, Cyprodinil, Pyrimidine, Pyramid, Pyrimidine, Pyrimidine, Phenoxyquin, Propoxyquin, Fluclozolin, Fluclozolin, Ethylpyrimidine, Sclerotin, Iprodione, Procymidone, Vinclozolin, Paddyfield, Isoprofen, Fenoxycarb, Iodocarb, Natamycin, Fluoxapiproline, Fluoxaproline , spiroxabiocin, fenpyraclostrobin, fenpyraclostrobin, polyoxin, fenpyraclostrobin, flumorph, fenpyraclostrobin, dimethomorph, benzathiapiprolin, benzathiapiprolin, valamoxaline, pyroquinone, tricyclazole, dichloropyraclostrobin, cyproconazole, pyraclostrobin, tolprocarb, activated ester, allylbenzazole, thiazolamide, isothiazamide, cymoxanil, cyfluthrin, pyrimidine, tetrazolylpyram, isobutylethoxyquin, Jinggangmycin, dodecacyclic morpholine, Flutianil, Ipflufenoquin, Quinofumelin, Aminopyrifen, Dipymetitrone, Flufenoxadiazam, Metarylpicoxamid, Flumetylsulforim or cintamidine; More preferably, the active ingredient B is selected from any one or a combination of at least two of the following bactericides B1-B5: (B1) Azoles fungicides, including: cyproconazole, difenoconazole, epoxiconazole, hexaconazole, clofoconazole, metconazole, propiconazole, tebuconazole, prothioconazole, Fluoxytioconazole, prochloraz or pyraclostrobin; (B2) mitochondrial electron transport chain complex III inhibitors, including: azoxystrobin, pyraclostrobin, syringystrobin, enoxastrobin, picoxystrobin, fenoxastrobin or mandestrobin; (B3) SDHI fungicides, including: Fluopyram, Triflupyridam, Benzovinfluxazole, Bixafen, Fluopyram, Inpyrfluxam, Fluopyram, Penthiopyrad, Fluopyram, Isoflucypram, Fluopyram, Boscalid, Bixafen, Fenoxam or Pyrapropoyne; (B4) Multi-site contact fungicides, including: chlorothalonil, mancozeb, propineb, thiabendazim or captan; (B5) Other fungicides: Metalaxyl-M, Ethiopyrimidine sulfonate, Ethiopyrimidine, Quinclorac, Benomyl, Carbendazim, Methyl Thiophanate, Dithiocarb, Fluopyram, Fluopyram, Cyanocobamide, Cyanopyram, Metraconazole, Pyriofenone, Cyazofamid, Indazolesulfamide, Fenpicoxamid, Nifenoxystrobin, Fluazinam, Cyprodinil, Myrimidine, Myrimidine, Fenpicoxamide, Fludioxonil, Sclerotinol, Iprodione, Procymidone, Vinclorac, Iodocarb, Iodocarb, Natamycin, Fluoxapiproline, Spirocyclanil, Amine Pyraclostrobin, Fenhexamid, Polyoxin, Dimethomorph, Flumorph, Butamorph, Dimethomorph, Benthiopyrad, Valamycin, Valicylide, Pyroquilone, Tricyclazole, Cyproconazole, Papyramide, Tolprocarb, Activated Ester, Cymoxanil, Tetrazolylpyram, Jinggangmycin, Flutianil, Ipflufenoquin, Quinofumelin, Aminopyrifen, Dipymetitrone, Flufenoxadiazam, Metarylpicoxamid, Flumetylsulforim, or Cyproconazole.

5. The pharmaceutical composition containing a pyrazole ether compound according to any one of claims 1 to 4, characterized in that: The pharmaceutical composition comprises a combination of active ingredients A and B1; Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B2; Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B3; Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B4; Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B5; Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B1 and B2; Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B1 and B3; Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B1 and B4; Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B1 and B5; Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B2 and B3; Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B2 and B4; Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B2 and B5; Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B3 and B4; Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B3 and B5; Preferably, the pharmaceutical composition comprises a combination of active ingredients A and B4 and B5.

6. The pharmaceutical composition containing a pyrazole ether compound according to any one of claims 1 to 4, characterized in that: The weight ratio of the active ingredient A to the active ingredient B is 1:0.02-100; Preferably, the active ingredient B is any one of the following B1: cyproconazole, difenoconazole, epoxiconazole, hexaconazole, clofoconazole, metconazole, propiconazole, tebuconazole, prothioconazole, Fluoxytioconazole, prochloraz or pyraclostrobin, and the weight ratio of the active ingredient A to the active ingredient B1 is 1:0.02-50, preferably 1:0.05-40; Preferably, the active ingredient B is any one of the following B2: azoxystrobin, pyraclostrobin, syringystrobin, enoxastrobin, picoxystrobin, fenoxastrobin, mandestrobin, and the weight ratio of the active ingredient A to the active ingredient B2 is 1:0.02-50, preferably 1:0.025-40; Preferably, the active ingredient B is any one of the following B3: Fluopyram, Triflupyridam, Benzovinflumizone, Bixafen, Fluopyram, Inpyrfluxam, Fluopyram, Penthiopyrad, Fluopyram, Isoflucypram, Fluopyram Hydroxylamide, Boscalid, Bixafen, Difenoconazole or Pyrapropoyne, and the weight ratio of the active ingredient A to the active ingredient B3 is 1:0.02-50, preferably 1:0.025-40; Preferably, the active ingredient B is any one of the following B4: chlorothalonil, mancozeb, propineb, zinc thiazole or captan, and the weight ratio of the active ingredient A to the active ingredient B4 is 1:0.02-100, preferably 1:0.033-20; Preferably, the active ingredient B is any one of the following B5: metalaxyl-M, ethidium sulfonate, ethidium, quinoline, benomyl, carbendazim, methyl thiophanate, ethiophencarb, fluopyram, fluopyram, cyanothiocarb, metrafenone, pyriofenone, cyazofamid, indazole sulfamate, fenpicoxamid, nitrobenzene, fluazinam, cyprodinil, pyrimidine, pyrimidine, pyrimidine, fenpicoxamid, flutolanil, sclerotinol, isoprodinil, procymidone, vinclozolin, rice blast, isoprodinil, propamocarb, iodocarb, natamycin, fluoxapiproline, spiroxabiocin, anthracene, fenamycin, polyantimycin The active ingredient A is selected from the group consisting of dimethomorph, flumorph, dipymorph, dimethomorph, dimethomorph, benzathiapiprolin, valeric acid, valeric acid amine, pyroquilone, tricyclazole, cyproconazole, rice blastamide, Tolprocarb, activated ester, cymoxanil, tetrazolylpyram, Jinggangmycin, Flutianil, Ipflufenoquin, Quinofumelin, Aminopyrifen, Dipymetitrone, Flufenoxadiazam, Metarylpicoxamid, Flumetylsulforim or cintamidine, wherein the weight ratio of active ingredient A to active ingredient B5 is 1:0.02-100, preferably 1:0.033-40; Preferably, the active ingredient B is a combination of B1 and B2, the active ingredient A is any one of compound 2, compound 3 or compound 6, the active ingredient B1 is any one of cyproconazole, difenoconazole, epoxiconazole, hexaconazole, clofoconazole, metconazole, propiconazole, tebuconazole, prothioconazole, Fluoxytioconazole, prochloraz or pyraclostrobin, the active ingredient B2 is any one of azoxystrobin, pyraclostrobin, syringoxystrobin, enoxastrobin, picoxystrobin, difenoconazole or mandestrobin, and the weight ratio of the active ingredient A to the active ingredient (B1+B2) is 1:0.02-50, preferably 1:0.05-30; Preferably, the active ingredient B is a combination of B1 and B3; the active ingredient A is any one of compound 2, compound 3, and compound 6; the active ingredient B1 is any one of cyproconazole, prothioconazole, difenoconazole, epoxiconazole, diniconazole, flusilazole, flutriafol, tebuconazole, hexaconazole, myclobutanil, penconazole, propiconazole, or tetrafluconazole; the active ingredient B3 is any one of fluopyram, triflupyridam, benzovinflumazole, bixafen, flupyraclostrobin, Inpyrfluxam, fluopyram, penthiopyrad, fluoxazopyrad, isoflucypram, fluopyram hydroxylamine, boscalid, bixafen, difenoconazole, or pyrapropoyne; and the weight ratio of the active ingredient A to the active ingredient (B1+B3) is 1:0.02-50, preferably 1:0.025-40; Preferably, the active ingredient B is a combination of B1 and B4; the active ingredient A is any one of compound 2, compound 3 or compound 6; the active ingredient B1 is any one of cyproconazole, prothioconazole, difenoconazole, epoxiconazole, diniconazole, flusilazole, flutriafol, tebuconazole, hexaconazole, myclobutanil, penconazole, propiconazole or tetrafluconazole; the active ingredient B4 is any one of chlorothalonil, mancozeb, propineb, zinc thiazole or captan; the weight ratio of the active ingredient A to the active ingredient (B1+B4) is 1:0.02-100, preferably 1:0.025-64; Preferably, the active ingredient B is a combination of B1 and B5; the active ingredient A is any one of compound 2, compound 3 or compound 6; the active ingredient B1 is any one of cyproconazole, prothioconazole, difenoconazole, epoxiconazole, diniconazole, flusilazole, flutriafol, tebuconazole, hexaconazole, myclobutanil, penconazole, propiconazole or tetrafluconazole; the active ingredient B5 is any one of metalaxyl-M, ethiprole sulfonate, ethiprole, quinacridone, benomyl, Carbendazim, methyl thiophanate, ethotripsy, benzyl oxadiazine, fluopyram, fluopyram, cyanothiocarb, mefenamic acid, pyriofenone, cyanazofamid, indazole sulfamethoxam, fenpicoxamid, nitrobenzene, fluazinam, cyprodinil, pyraclostrobin, pyrimethanil, fenmethanil, flutolanil, fludioxonil, sclerotin, chloranil, procymidone, vinclozolin, blasting agent, isoblasting agent, propamocarb, iodocarb, Natamy any one of cin, fluthiazolin, fluoxapiproline, spiroxabiocin, fenpyraclostrobin, fenhexamid, polyoxin, oxadiazine, flumorph, butylpyraclostrobin, dimethomorph, benzathiapiproline, benzathiapiproline, valeric acid, valeric acid, pyroquilone, tricyclazole, cyproconazole, rice blastamide, tolprocarb, activated ester, cymoxanil, tetrazolylpyram, Jinggangmycin, Flutianil, Ipflufenoquin, Quinofumelin, Aminopyrifen, Dipymetitrone, Flufenoxadiazam, Metarylpicoxamid, Flumetylsulforim or cinbamimid, the weight ratio of active ingredient A to active ingredient (B1+B5) is 1:0.02-100, preferably 1:0.025-25; Preferably, the active ingredient B is a combination of B2 and B3; the active ingredient A is any one of compound 2, compound 3 or compound 6; the active ingredient B2 is any one of azoxystrobin, pyraclostrobin, syringosterone, enoxastrobin, picoxystrobin, fenoxstrobin or Mandestrobin; the active ingredient B3 is any one of fluopyram, triflupyridam, benzovinflumazole, bixafen, fluopyram, inpyrfluxam, fluopyram, penthiopyrad, fluoxazolidinone, isoflucypram, fluopyram hydroxylamine, boscalid, bixafen, fenoxathiapiprolin or Pyrapropoyne; the weight ratio of active ingredient A to active ingredient (B2+B3) is 1:0.02-50, preferably 1:0.04-25; Preferably, the active ingredient B is a combination of B2 and B4; when the active ingredient A is any one of compound 2, compound 3 or compound 6, the active ingredient B2 is any one of azoxystrobin, pyraclostrobin, syringosterone, enoxastrobin, picoxystrobin, fenoxastrobin or Mandestrobin, and the active ingredient B4 is any one of chlorothalonil, mancozeb, propineb, zinc thiazole or captan, and the weight ratio of the active ingredient A to the active ingredient (B2+B4) is 1:0.02-100, preferably 1:0.033-20; Preferably, the active ingredient B is a combination of B2 and B5; the active ingredient A is any one of compound 2, compound 3 or compound 6; the active ingredient B2 is any one of azoxystrobin, pyraclostrobin, syringosterone, enoxastrobin, picoxystrobin, fenoxystrobin and mandestrobin; the active ingredient B5 is any one of metalaxyl-M, pyrimidine sulfonate, pyrimidine, quinoline, benomyl, carbendazim, methylthiophanate, ethotripsy, benomyl, fluopyram, fluopyram, cyanooxystrobin, metrafenone, pyriofenone, cyanazofamid, indazole sulfamethoxam, fenpicoxamid, nitrobenzene, fluazinam, cyprodinil, pyrimidine, pyrimidine, fenpicoxamid, flutolanil, sclerotin, isoprodinil, procymidone, vinclozolin, rice blast, isoprodinil, propamocarb, iodocarb, natamycin n, any one of fluthiazolin, fluoxapiproline, spiroxabiocin, fenpyraclostrobin, fenhexamid, polyoxin, oxadiazine, flumorph, pyrimorph, dimethomorph, benzathiapiproline, benzathiapiproline, valeric acid, valeric acid, pyroquilone, tricyclazole, cyproconazole, pyraclostrobin, tolprocarb, activated ester, cymoxanil, tetrazolylpyram, Jinggangmycin, Flutianil, quinofumelin, aminopyrifen, dipymetitrone, flufenoxadiazam, metarylpicoxamid, flumetylsulforim or cinbendazole, the weight ratio of active ingredient A to active ingredient (B2+B5) is 1:0.02-100, preferably 1:0.05-20; Preferably, the active ingredient B is a combination of B3 and B4; the active ingredient A is any one of compound 2, compound 3 or compound 6, the active ingredient B3 is any one of fluopyram, triflupyridam, benzovinflumazole, bixafen, fluopyram, inpyrfluxam, fluopyram, penthiopyrad, fluoxazolidinone, isoflurane, fluopyram, boscalid, bixafen, difenoconazole, and Pyrapropoyne, the active ingredient B4 is any one of thiophanate-methyl, mancozeb, propineb, zinc thiabendazole or captan, and the weight ratio of the active ingredient A to the active ingredient (B3+B4) is 1:0.02-100, preferably 1:0.05-40; Preferably, the active ingredient B is a combination of B3 and B5; the active ingredient A is any one of compound 2, compound 3 or compound 6, and the active ingredient B3 is: Fluopyram, Triflupyridam, Benzovinfluxazole, Bixafen, Fluopyram, Inpyrfluxam, Fluopyram, Penthiopyrad, Fluoxathiapiprolin, Isoflucypram, Fluopyram, Boscalid, Bixafen, Fenoxazolam or Pyrapropoyne When any one of the above is used, the active ingredient B5 is: metalaxyl-M, ethiminol sulfonate, ethiminol, quinoline, benomyl, carbendazim, methyl thiophanate, ethotripsy, fluopyram, fluopyram, cyanothiocarb, metrafenone, pyriofenone, cyazofamid, indazole sulfamate, fenpicoxamid, nitrobenzene, fluazinam, cyprodinil, pyraclostrobin, pyrimethanil, fenpyroxil, fludioxonil, sclerotin, isoprodinil, procymidone, vinclozolin, and rice blast. , Isopropylamine, Cyproconazole, Iodocarb, Natamycin, Fluoxapiproline, Spirocyclamide, Amitriptyline, Cyclohexanil, Polyoxin, Dimethomorph, Flumorph, Dipymorph, Dimethomorph, Dimethomorph, Dimethomorph, Dimethomorph, Valamycin, Valamycin, Pyroquilone, Tricyclazole, Cyproconazole, Rice Blastamide, Tolprocarb, Activated Ester, Cymoxanil, Tetrazolylpyram, Jinggangmycin, Flutianil, Ipflufenoquin, Quinofumelin, Aminopyrifen, Dipymetitrone, Flufenoxadiazam, Metarylpicoxamid, Flumetylsulforim or Sinpyram, the weight ratio of active ingredient A to active ingredient (B3+B5) is 1:0.02-100, preferably 1:0.025-40; Preferably, the active ingredient B is a combination of B4 and B5, the active ingredient A is any one of compound 2, compound 3 or compound 6, the active ingredient B4 is any one of chlorothalonil, mancozeb, propineb, zinc thiazole or captan, and the active ingredient B5 is metalaxyl-M, ethidium sulfonate, ethidium sulfonate, quinocadone, benomyl, carbendazim, methylthiophanate, ethidium sulfonate, zoxanil, fluopyram, fluopyram, cyanobacterium ester, metrafenone, pyriofenone, cyanazofamid, indazole sulfaquinoxamid, fenpicoxamid, nitrobenzene, fluazinam, cyprodinil, pyrimidine, pyrimidine, fenpicoxamid, flutolanil, sclerotinol, isoprodinil, procymidone, vinclozolin, rice blast, isoprodinil, propamocarb, iodocarb, natamycin, fluoxapip The invention relates to any one of roline, spiroxabiocin, fenpyraclostrobin, fenpyraclostrobin, polyoxin, oxadiazine, flumorph, butylpyraclostrobin, dimethomorph, benzathiapyr, valeric acid, valeric acid, pyroquilone, tricyclazole, cyproconazole, rice blastamide, Tolprocarb, activated ester, cymoxanil, tetrazolium pyrazone, Jinggangmycin, Flutianil, Ipflufenoquin, Quinofumelin, Aminopyrifen, Dipymetitrone, Flufenoxadiazam, Metarylpicoxamid, Flumetylsulforim or cintamidine, wherein the weight ratio of the active ingredient A to the active ingredient (B4+B5) is 1:0.02-100, preferably 1:0.025-20.

7. A pharmaceutical preparation, characterized in that The pharmaceutical preparation comprises the pharmaceutical composition containing a pyrazole ether compound as claimed in any one of claims 1 to 6 and a pesticide acceptable carrier; Preferably, in the pharmaceutical preparation, the weight percentage of the pharmaceutical composition containing the pyrazole ether compound is 0.1-99%; Preferably, the dosage form of the pharmaceutical preparation is an aqueous emulsion, a microemulsion, a suspension, a suspoemulsion, a soluble solution, a dispersible solution, an emulsifiable concentrate, a powder, a wettable powder or a dispersible granule.

8. Use of the pharmaceutical composition containing a pyrazole ether compound according to any one of claims 1 to 6 or the pharmaceutical preparation according to claim 7 in preventing and controlling plant diseases in agriculture, forestry and horticulture.

9. Use of the pharmaceutical composition containing a pyrazole ether compound according to any one of claims 1 to 6 or the pharmaceutical preparation according to claim 7 in seed treatment of plants, crops or flowers.

10. A method for preventing and controlling plant diseases, characterized in that: The method comprises: applying an effective dose of the pharmaceutical composition containing the pyrazole ether compound according to any one of claims 1 to 6 or the pharmaceutical preparation according to claim 7 to the plant disease to be controlled or the medium in which it grows.

Images